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Abstract 
Purpose: Pathological and age-related declines in both physical fitness and muscle 
function are well established; however, the role mitochondrial function plays in these 
changes is less understood. With low skeletal muscle mass and function associated 
with poorer surgical outcomes, treatments and interventions that can limit the 
decrease in muscle mass and function seen in the elderly, known as sarcopenia, and 
in those with cancer, known as cancer cachexia, is vital.  
Methods: A systematic review and meta-analysis was conducted to determine the 
impact of sarcopenia on overall and disease-free survival in patients with locally 
advanced rectal cancer. In addition, young and older healthy volunteers were 
recruited to determine links between advancing age and declines in global physical 
fitness and muscle function, as well as investigate if similar declines in mitochondrial 
function occur. 
Results: Our systematic review and meta-analysis established that pre-existing 
sarcopenia was associated with shorter overall and disease-free survival in patients 
with locally advanced rectal cancer. Within our healthy volunteer cohort, age 
significantly impacted global physical function (HGS, 1-RM and VO2max) and 
measures of muscle architecture, with reduced status in older adults. Conversely, 
mitochondrial function was not different between the age-groups. 
Conclusions: There is clearly an age-related decline in global physical fitness and 
muscle function, however it remains unknown to what degree mitochondrial function 
is implicated in these changes. With sarcopenia and cachexia both having a negative 
impact on various prognostic outcomes, interventions such as exercise training 
regimes show promising results in improving cardiovascular fitness and muscle 
University of Nottingham  Abbreviations 
mass/ function in both elderly and cancer patients undergoing surgery. Despite this, 
if or how these interventions may modify any mitochondrial dysfunction that may 
exist, especially in cancer patients undergoing neoadjuvant treatment prior to 
surgery is wholly unknown. More research is required to understand the complex 
relationship between mitochondrial function and the changes seen in the skeletal 
muscle of both the elderly and cancer patients. 
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1.1  Chapter focus 
This chapter will introduce the importance of skeletal muscle as an organ in the 
maintenance of whole-body health across the life-course and in the presence of a 
cancer. Skeletal muscle mitochondria will be afforded specific consideration, as the 
organelle is responsible for most of the cellular energy generation, as well as playing 
roles vital in preserving cellular health. To date mitochondrial function is a largely 
understudied topic in the context of its impact of physical function with ageing and 
disease. Finally, the growing evidence relating to the role of exercise training 
programs as a tool to prevent muscle loss and improve clinical outcomes in both 




1.2 Skeletal muscle  
Skeletal muscle represents one of the major components of the human body, 
accounting for  40% of total body mass in non-obese individuals (Romanello & 
Sandri, 2016). Skeletal muscle is a dynamic and plastic structure, containing 50 - 
75% of all body protein and accounting for 30 – 50% of whole body protein turnover 
(Frontera & Ochala, 2015). By converting chemical energy, through the oxidation of 
metabolic substrates, to mechanical work at myosin cross bridges, skeletal muscle is 
able to generate force and power that maintains posture and produces movement 
that influences activity (Barclay, 2017). From a metabolic perspective, skeletal 
muscle contributes to basal energy metabolism, serves as a store for substrates 
such as amino acids and carbohydrates, generates heat to maintain core 
temperature and is the consumer of the majority of oxygen and fuel used in physical 
activity and exercise (Frontera & Ochala, 2015). Skeletal muscle also has well-
established roles in maintaining whole body health in situations of obesity, ageing 
and chronic disease (Vanderveen et al., 2017). 
1.2.1 Structure and types 
The architecture of skeletal muscle is characterised by a very particular and well 
described arrangement of muscle fibres (myofibers) and associated connective 
tissue (Frontera & Ochala, 2015). Each myofiber is a single, multinucleated, long 
cylindrical cell contained within a cell membrane; the sarcolemma (Barrett et al., 
2016). Individual muscle fibres are made up of thousands of myofibrils, which are 
composed of billions of myofilaments. The myofilaments contain several proteins that 
together make up the basic contractile machinery of the skeletal muscle, known as 
the sarcomere. Bundles of myofibers form the fascicles, and bundles of fascicles 
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form the muscle tissue, with each layer encapsulated by the extracellular matrix, and 
supported by the cytoskeletal network (Mukund & Subramaniam, 2020). The two 
most abundant myofilaments, comprising of 70 – 80% of total protein content of a 
single fibre, are actin and myosin (Frontera & Ochala, 2015) (Figure 1).  
 
Figure 1 - Structure of skeletal muscle (Sherwood, 2010) 
 
Other important cellular elements within the muscle fibre include the transverse 
tubular system (T tubules), the sarcoplasmic reticulum and the mitochondrial 
network. The T tubules and sarcoplasmic reticulum play important roles in muscle 
activation whilst the mitochondrial network provides much of the energy needed for 





Human skeletal muscle is a heterogeneous tissue and is frequently classified into 
two main types: “slow” and “fast”. Different muscles are composed of varying 
amounts of three types of muscle fibres, which allow them to participate in activities 
of various metabolic and mechanical demands. Type I muscle is highly vascularised 
and saturated with mitochondria and myoglobin (Mukund & Subramaniam, 2020). 
They are fatigue resistant, contracting for long period of time but generating little 
force, and are found in abundance in elite endurance athletes (Carter et al., 2015). 
Type II fibres, which consist of IIa and IIx fibres, are larger, contain less mitochondria 
and are therefore more fatigable than type I fibres, however can generate more force 
and are seen in higher proportion in elite strength and power athletes (Carter et al., 
2015).  
1.2.2 Muscle contraction and force generation 
Fundamentally, muscle contraction is the result of the thin actin myofilament sliding 
over the thick myosin myofilament within muscle cells. This process, known as the 
sliding filament theory, was first described in 1954 by Huxley et al,. (A. F. Huxley & 
Niedergerke, 1954; H. Huxley & Hanson, 1954) and remains the accepted 




Figure 2 – The sliding filament model of muscle contraction theory (Biga & Dawson, 2010) 
 
Contraction of muscle is initiated by a nerve action potential being transmitted via T 
tubules of a muscle fibre and leading to the release of calcium (Ca2+) from the 
sarcoplasmic reticulum. The free Ca2+ then binds to the regulatory protein, troponin 
C, which, in the resting state is usually bound to the active site of actin. The binding 
of Ca2+ triggers a conformational change in troponin allowing the myosin head to 
bind to actin (Barrett et al., 2016). This creates a cross bridge between the 
myofilaments. Available ATP then binds to the myosin with the ATPase activity of 
myosin hydrolysing ATP to adenosine diphosphate (ADP) and free phosphate 
(Mukund & Subramaniam, 2020). This process allows myosin to move along the 
actin myofilament, resulting in an increased overlap within the muscle cell (Figure 2). 
The individual force generated from actin-myosin cross bridges is transmitted 
longitudinally and laterally within the fibre and produce movement when the forces 




1.2.3 Energy production 
All muscle actions require energy, and most activities involve different energy 
pathways at different points of time using a combination of carbohydrates and lipids 
(Barrett et al., 2016). The main energy source for cellular metabolism is glucose, 
which is catabolised in three subsequent processes; glycolysis, the tricarboxylic acid 
cycle (TCA), and oxidative phosphorylation (OXPHOS), to produce ATP (Bonora et 
al., 2012). Glycolysis involves two distinct phases in which glucose is cleaved into 
two pyruvate molecules (Chaudhry & Varacallo, 2018). The first phase requires the 
usage of two ATP molecules, with the second phase creating ATP and NADH 
molecules (Lenzen, 2014) Activities that last for just a few minutes can be sustained 
through the production of ATP via anaerobic glycolysis, however this pathway 
produces lactate and H+ that impair muscle function and ultimately lead to fatigue 
(Frontera & Ochala, 2015). Energy required for any sustained duration is supplied by 
the other two main metabolic pathways, which occurs within the three-dimensional 
mitochondrial network of aerobic cells (Berg et al., 2002).  
1.3 Mitochondria – the powerhouse of the cell 
Literature reports that mitochondria arose ~2 billion years ago when a bacterium 
fused with an archaeal cell (Pollard et al., 2017). Mitochondria are highly dynamic 
organelles that provide 95% of cellular energy needs (Feng et al., 2018). The 
organelle comprise of two separate and functionally distinct outer and inner 
membranes that incapsulate the intermembrane space and matrix compartments 
(Nunnari & Suomalainen, 2012). Within the matrix is their own genome, which 




In skeletal muscle, mitochondria exist in two distinct morphologies: subsarcolemmal 
(SSM) and interfibrillar (IFM). This network of mitochondria forms a conductive 
pathway that can rapidly distribute energy to myofibrils, allowing muscles to 
immediately respond to changes in energy requirements (Romanello & Sandri, 
2016). The most abundant subpopulation, accounting for 80% of total skeletal 
muscle mitochondria, are IFM which reside in between the myofilaments (Lundby & 
Jacobs, 2016). IFM are mostly responsible for the synthesis of ATP required for 
contractile activity and appear to be more affected than SSM by ageing and chronic 
age associated conditions, such as diabetes and cancer (Di Lisa & Scorrano, 2012). 
SSM are located beneath the sarcolemma and have been shown to utilise less 
oxygen than IFM (Lai et al., 2019) and are thought to be more involved in signalling 
processes (Wahwah et al., 2020). 
1.3.1 Essential roles of mitochondrial network 
One of the main roles of the mitochondria is the production of ATP. ATP is generated 
during the reactions of the TCA cycle, located in the matrix, and via OXPHOS, that 
occurs at the inner mitochondrial membrane (Bishop et al., 2014). OXPHOS is the 
main source of energy production in eukaryotic cells and is performed by means of 
four enzyme complexes known as the electron transport system. Through the 
utilisation of energy from the chemical bonds of glucose and fatty acids, the 
complexes generate an electrochemical proton gradient across the inner membrane 
that enables the fifth enzyme complex – ATP synthase to generate ATP from ADP 
and inorganic phosphate (Chaban et al., 2014; Pollard et al., 2017). The 
mitochondrial network is also involved in a number of other vital cellular processes 
including the synthesis of various amino and fatty acids (Spinelli & Haigis, 2018). It is 
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also the major intracellular site for producing reactive oxygen species (ROS) (Zhao 
et al., 2019), is involved in ionic homeostasis (O’Rourke et al., 2005), and has a role 
in the regulation of all modalities for cell death (Di Lisa & Scorrano, 2012). 
 
Since the mitochondria is involved in multiple aspects of cellular function, it is 
unsurprising that mitochondrial networks are heavily integrated in cell signalling 
pathways (Tait & Green, 2012). A growing body of data suggests that mitochondrial 
signalling pathways are not just reactive but also actively provides signals back to 
the nucleus (Weinberg et al., 2015). In general, mitochondria can regulate cell 
signalling through two means; serving as a physical platform on which protein-
protein signalling interactions occur, and by regulating the levels of key intracellular 
signalling molecules including Ca2+ and ROS (Tait & Green, 2012). Calcium ion 
concentration is a key regulator of various signalling pathways including nervous 
system excitability, the contraction of muscles and activation of enzymes (Song et 
al., 2019). Mitochondria can accumulate  up to 20-fold higher concentrations than the 
cytosol (Anderson et al., 2019), and can therefore function as a buffering system to 
help restore homeostasis, as well as initiate signalling pathways by releasing these 
stores. Mitochondrial Ca2+ regulation is known to influence hormone secretion 
(Wiederkehr et al., 2011), tissue regeneration (Antony et al., 2016) and cytokine 
signalling associated with innate immunity (Cheng et al., 2016). 
1.3.2 Maintaining mitochondrial homeostasis 
In healthy skeletal muscle fibres, the mitochondrial content reflects that of the energy 
requirement (Devin & Rigoulet, 2007). Mitochondrial dynamics encompass 
processes associated with mitochondrial fission and fusion, the degree of biogenesis 
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and the induction of mitophagy (Senft & Ronai, 2016). It is these activities that 
determine the balance between energy production and cell death. 
 
Mitochondrial biogenesis is a critical process for determining the number and 
function of the organelle and is influenced by several factors such as exercise 
training, oxidative stress, muscle regeneration and inflammation (van der Ende et al., 
2018). Once activated, signalling cascades and transcriptional processes result in 
the synthesis of mitochondrial proteins and replication of the mitochondrial genome. 
This results in the expansion of mitochondrial structures and enlargement of the 
mitochondria (Pustylnikov et al., 2018). These enlarged mitochondria then undergo 
fission, leading to an increase in mitochondrial mass.  
 
Fission, or division, of mitochondria produces one or more daughter mitochondria 
and fragments the network into unconnected, shorter organelles. It is required to 
transmit the organelles among dividing cells and when there is an increase in energy 
demands. Additionally, fission is a mechanism that segregates dysfunctional or 
damaged components of the mitochondria, allowing their removal from the network 
(Romanello & Sandri, 2016). Counterpart to fission is fusion, which unifies 
mitochondria, leading to elongated organelles with increased interconnectivity.  This 
process allows the exchange of material between healthy mitochondria (Ni et al., 
2015). Under conditions of high energy demand, fusion allows optimal function by 
increasing the bioenergetic capacity of the cell as well as protecting the mitochondria 
from mitophagy (Romanello & Sandri, 2016). This highly dynamic cycle of fusion and 
fission balances two competing processes. Fusion allows mitochondria to 
compensate for individual organelles defects by sharing components, thereby 
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helping to maintain energy output in conditions of increased cellular stress (Youle & 
Van Der Bliek, 2012). On the other hand, fission segregates the most seriously 
damaged mitochondria to preserve the health of the overall mitochondrial network.  
 
Considerable progress has been made in identifying the molecular regulation of 
mitochondrial fusion and fission. Regulation is thought to be achieved mainly by 
mitochondrial shaping proteins known as dynamin related proteins (DRP) (R. Yu et 
al., 2020). Fusion is controlled by three key DRPs (mitofusin 1, mitofusin 2 and optic 
atriophy 1) that once activated, allows fusion to proceed in a step wise process. 
Firstly, the two mitochondria are tethered together and form a ring structure at the 
contact point between the outer membranes. Through a process triggered by 
guanosine triphosphate (GTP) hydrolysis, the two outer membranes fuse together, 
followed by a final fusion of two inner membranes (Brandt et al., 2016; Tilokani et al., 
2018). The molecular regulation of mitochondrial fission is slightly less understood, 
however is known to involve specific DRPs being recruited to the mitochondrial 
surface triggering mitochondrial fission through GTPase activity (Otera et al., 2013). 
Recent data also shows that co-factors such as the endoplasmic reticulum and actin 
cytoskeleton also play a role in facilitating fission (R. Yu et al., 2020), with these 
factors suggested to wrap around the mitochondria and mark prospective sites for 
division. 
 
Mitochondrial turnover is predominantly carried out by autophagy, a cellular 
housekeeping system that degrades mitochondria as well as other cellular 
components (Peterson et al., 2012). When a certain threshold of damage is reached, 
mitochondrial are removed through this system, referred to as mitophagy, a highly 
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selective process that removes organelles that are either damaged, long lived, or 
misfolded. Mitophagy, together with biogenesis, is essential in maintaining a healthy 
population of mitochondria (van der Ende et al., 2018). 
 
A fine equilibrium of mitochondrial dynamics is required to preserve muscle mass 
and prevent muscle wasting. For example, loss of mitochondrial fusion results in 
muscle atrophy and reduced mitochondrial DNA, whilst failure in mitophagy leads to 
the accumulation of damaged organelles that can impact sensitivity to cell death, 
increase inflammatory cytokine production and possibly reduce antiviral response 
(Tait & Green, 2012; Vanderveen et al., 2017). More recently, studies have shown 
that a disturbance in the balance between fusion and fission is involved in the 
progression of several types of neoplasms (L. Chen et al., 2018). 
1.3.3 Assessing mitochondrial function 
Given the critical role skeletal muscle mitochondria play in several cellular processes 
both in health and disease, measuring their function is vital in furthering our 
understanding. There are several methods available, including non-invasive in vivo 
and in vitro techniques using fresh tissue samples.  
 
Since the reduction of oxygen is a necessary precursor event to ATP synthesis, 
mitochondrial capacity can be assessed in vivo from the rate of oxygen consumption 
(Lanza & Nair, 2010). At a whole-body level, the maximal rate at which an individual 
consumes oxygen is referred to as VO2max. As activity level increases, oxygen 
consumption by skeletal muscle consumes a larger fraction of the total body oxygen 
uptake. Therefore maximum oxygen consumption is postulated to provide an 
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estimate of muscle oxygen consumption and thus mitochondrial function (Liu & 
Marcinek, 2017). Although several studies have shown a linear relationship between 
VO2max and muscle mitochondria content and capacity (Hoppeler, 1990; Van Der 
Zwaard et al., 2016), VO2max is also a function of the oxygen carrying capacity of the 
blood, tissue perfusion and cardiac output. It is therefore impossible to gain any 
tissue specific information using this method (Lanza & Nair, 2010). This is why the 
measure of in vitro tissue is preferable to obtain an accurate assessment of 
mitochondrial capacity. 
 
High resolution respirometry (HRR) has emerged as a powerful tool for in vitro 
measurement of isolated mitochondrial respiratory capacity (Lanza & Nair, 2010). 
The process involves permeabilised muscle fibres being added to a twin chambered 
instrument before sequentially titrating substrates, inhibitors and uncouplers to 
measure mitochondrial respiration at different stages. For instance, the maximum 
oxidative capacity of mitochondrial respiration can be determined following the 
addition of certain substrates, whilst the addition of an uncoupler can allow the 
maximum respiratory capacity of the mitochondria to be recorded (Porter et al., 
2015).  
 
The main advantage of HRR, which is now seen as the gold standard for in vitro 
assessment of mitochondrial function, is that multiple measurements can be gained 
from the same, very small sample of permeabilised muscle fibres. In addition, this 
method can provide mechanistic insight into the effects environmental interventions, 
such as exercise training and nutritional supplementation (Christensen et al., 2016), 
as well as the impact ageing (Greco et al., 2003; Hutter et al., 2004; Porter et al., 
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2015) and chronic disease (Buck et al., 2017) can have on mitochondrial function. 
The main disadvantage of HRR is that, unless used with measurements of physical 
function (e.g., cardiorespiratory fitness or muscle function), the conclusions gained 
can be difficult to apply clinically.  
1.4 The effect of ageing on muscle function 
Growing old, or chronological ageing, is unavoidable and is defined as the 
progressive deteriorative changes seen during the adult period of life that underlie an 
increasing vulnerability to challenges and thereby decrease the ability of the 
organism to survive (Mosoro, 2017). Overall, the common denominator of ageing is 
an accumulation of damage to genetic material, which ultimately leads to the clinical 
effects seen in advancing age (Aunan et al., 2016). 
1.4.1 Sarcopenia 
One of the most distinctive features of ageing is the progressive loss of muscle 
mass, strength and physical function (Distefano et al., 2018). Muscle mass peaks 
around the middle of the 3rd decade of life, with a slow rate of decline then seen until 
the 5th decade. After this, the rate of muscle loss increases, ranging between 0.5% - 
1.4% loss each year (Carter et al., 2015). As such, muscle mass is predicted to 
reduce between 30 – 50% between the ages of 30 – 80 years (Milanović et al., 
2013). The implications of skeletal muscle loss are far reaching and can impact an 
individual’s ability to perform activities of daily living (ADLs), as well as being a 
precipitating factor in a decline in physical function, increased risk of frailty, disability 




The term sarcopenia was used for the first time by Rosenberg when referring to 
progressive loss of lean body mass seen in ageing (Rosenberg, 1997). The definition 
has since been expanded to include the presence of lower muscle mass and 
weakness and/or impaired performance, with muscle strength the most reliable 
measure (Cruz-Jentoft et al., 2010, 2019). The aetiology of sarcopenia is 
multifactorial and includes alterations in variables such as nutritional status, physical 
activity levels and hormone concentrations (Joseph et al., 2016). It is estimated the 
prevalence of sarcopenia in the older population ranges between 4 – 27% depending 
on gender and country (Frontera & Ochala, 2015). Sarcopenia has financial 
implications to healthcare systems. For example, among older adults that are 
hospitalised, those with sarcopenia are 5 times more likely to generate higher 
hospital costs than those without (Cruz-Jentoft et al., 2019). 
 
As individuals age, changes in skeletal mass and strength are dissociated, with 
muscle strength declining three times faster than mass (Peterson et al., 2012). This 
suggests that whilst an overall reduction in the muscle size is a contributor to 
sarcopenia, it is not the only change seen in ageing skeletal muscle. Architectural 
and molecular changes such as shifts in muscle fibre type distribution (Deschenes, 
2004; Larsson & Karlsson, 1978; Lexell et al., 1988), changes in protein synthesis 
(Evans, 2010), myeosteatosis (Delmonico et al., 2009) and increased fibrosis are 
also seen with advancing age (Boengler et al., 2017). In addition, recent work has 
highlighted changes in neuromuscular communication with advancing age 
(Gonzalez-Freire et al., 2014). These changes indicate that a decrease in muscle 
quality also plays a role in the functional changes seen in sarcopenia.  
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1.4.2 Ageing and mitochondrial function 
It is becoming increasingly clear that mitochondria play a critical role in the loss of 
skeletal muscle function seen in ageing and chronic disease (Liu & Marcinek, 2017). 
Ageing has been shown to be associated with an accumulation of abnormally 
enlarged and round mitochondria (Peterson et al., 2012; Sebastián et al., 2017). 
Additionally, there is an increased portion of mitochondria that are non-functional, 
something that is, in part, the result of an imbalance between efficient elimination of 
damaged mitochondria through mitophagy and appropriate mitochondrial biogenesis 
(Peterson et al., 2012). These changes result in the density of skeletal muscle 
mitochondria to drop substantially, something that has been shown with electron 
microscopy in the vastus lateralis muscle of people over 60 years old (Conley et al., 
2000). There is also an accumulative damage to mitochondrial DNA, which reduces 
the ability of mitochondria to generate ATP, resulting in further loss of function 
(Mosoro, 2017). The mitochondrial dysfunction seen is ageing is closely related to 
loss of skeletal muscle mass and can lead to a decrease in physical activity and 
increased the risk of falls in the elderly (Seo et al., 2016) (Figure 3). 
 





Mitochondria constitute the main source of ROS, a by-product of the energy 
producing process, oxidative phosphorylation (OXPHOS). Related to this, the free 
radical theory of ageing, which was first proposed by Harman et al. in 1956, 
suggested that the progressive mitochondrial dysfunction seen in ageing is the result 
of an increased production of ROS, which in turn causes further mitochondrial 
deterioration and global cellular damage (Harman, 1956). In recent years, this theory 
has been re-evaluated as it is now thought that ROS function as signalling 
molecules, activating compensatory homeostatic responses and are therefore 
needed for normal cellular function (López-Otín et al., 2013). As we age however, 
the level of cellular stress and damage increases, with a subsequent paralleled 
increase in the ROS level to maintain survival. It is now thought that when ROS 
production goes above a certain threshold, they aggravate rather than alleviate the 
age-associated damage resulting in a reduced lifespan of the cell or cell death 
(Aunan et al., 2016).  
 
Although the aetiology of sarcopenia is complex and multifunctional, the combined 
impairment of mitochondrial biogenesis and turnover contributes to the slow gradual 
loss of muscle mass seen in condition (Coen et al., 2019). One key area of ongoing 
research is whether the changes seen in mitochondrial function are an intrinsic 
property of ageing, or the result of reduced activity levels and as such, something 
that can be partly preventable (Liu & Marcinek, 2017). 
1.4.3 The role of exercise in ageing 
Even though a degree of age-related muscle loss is unavoidable, skeletal muscle 
maintains a high degree of plasticity throughout its life-course, and as such, age 
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associated decrements can be limited through modifiable lifestyle factors (Brook et 
al., 2016; Seo et al., 2016). Among these, physical activity is seen as the most 
effective intervention to attenuate the loss of muscle strength and mass seen with 
advancing age (Boengler et al., 2017).  
 
Resistance exercise training (RET) in the elderly has been shown to increase the 
size of muscle fibres, thereby increasing overall mass (Mosoro, 2017), and continues 
to be the most effective intervention against sarcopenia (Yoo et al., 2018). There is 
also considerable evidence to support the theory that aged muscle retains the 
capacity to elicit biogenesis in a manner similar to that of young muscle when 
exercised (Carter et al., 2015). This is thought to be due to the fact cumulative bouts 
of exercise induces several molecular ‘stresses’ on skeletal muscle. Amongst these 
is an increase in ROS production. As mentioned previously, although excessive 
production of ROS is associated with the pathogenesis of numerous diseases and 
ageing, when produced in low to moderate amounts, they act as key intracellular 
signalling molecules regulating a host of physiological and biological processes 
(Tryfidou et al., 2020). These processes include upregulating skeletal muscle gene 
expression, protein synthesis and oxidative capacity (Peterson et al., 2012). 
 
Whilst RET is primarily associated with skeletal muscle hypertrophy and strength 
gains, aerobic (or endurance) exercise training (EET) is predominantly associated 
with improvements in cardiorespiratory fitness (CRF) (Lin et al., 2015; Yoo et al., 
2018) as well as being a potent stimulus for mitochondrial biogenesis, increasing 
both fission and fusion and regulating organelle renewal through mitophagy (Russell 
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et al., 2014). Each of these adaptions aid mitochondrial turnover and improve 
skeletal muscle efficacy (Vanderveen et al., 2017).  
 
To date, there are conflicting opinions regarding the optimal exercise program that 
can be used to improve aspects of mitochondrial function, and whether mitochondrial 
content and function are altered the same with different forms of exercise (Bishop et 
al., 2014). Both human and animal models demonstrated increased mitochondrial 
enzyme activity and ATP production in response to an aerobic training program 
(Koltai et al., 2012; Uribe et al., 1992). More recently, animal models have shown 
that endurance training could stimulate the repair of mitochondrial DNA and allow for 
mitochondrial biogenesis (Safdar et al., 2016). It is important to note that although 
age-associated declines in mitochondrial function have been shown to be reduced in 
older adults who underwent EET, exercise training did not completely restore all 
aspects of mitochondrial function (Peterson et al., 2012). This suggests that although 
exercise can help attenuate age-associated changes in skeletal muscle 
mitochondria, it cannot completely prevent the onset of age-related mitochondrial 
decline (Carter et al., 2015). This indicates a need for further research to investigate 
these topics in aged individuals. 
1.5 Cancer 
Cancer has afflicted humanity for thousands of years. The first documented case of 
cancer was 2700 years ago, and cancerous growths have been found in Egyptian 
and Peruvian mummies dating back to 1500 BC (Faguet, 2015). Throughout history, 
the question of how cancer begins, and what are its causes, led to hypotheses and 
historic practices that have shaped our understanding and treatment of the disease 
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today. In the simplest form, cancer is a genetic disease. More precisely, it is a 
disease of gene expression, with different forms of cancer sharing common 
mechanisms governing uncontrolled cell proliferation and differentiation (Coleman, 
2018). Despite this common origin of uncontrolled gene expression, there is 
estimated to be more than 277 different types of cancer disease (Hassanpour & 
Dehghani, 2017).  
 
It is only in recent decades that the prevalence of cancer has markedly increased, 
largely due to a rapidly ageing population (White et al., 2014) and increasing ‘risky’ 
behaviour such as smoking, increased alcohol consumption and poor diet (Faguet, 
2015). In 2014, the World Health Organisation declared that cancer had become the 
biggest cause of mortality worldwide (Costa et al., 2016), and the most recent 
estimates suggest that in 2016 there were 17 million new cases of cancer worldwide 
with 9.6 million cancer related deaths (Cancer Research, 2020) 
1.5.1 Classification  
Cancer is classified in two ways, firstly by the type of tissue the cancer originates 
from, known as the histological type. Most cancers fall into one of three main groups: 
i) carcinomas, ii) sarcomas and iii) leukaemia and lymphomas. Carcinoma refers to a 
cancer originating from the epithelial lining of internal or external organs, such as 
lung, skin, prostate, and colon. They are solid tumours that can be divided further 
into adenocarcinoma and squamous cell carcinoma (U.S National Institutes of Heal, 
2020). Sarcomas are solid tumours of connective tissue such as muscle, bone, 
cartilage, and fibrous tissue. Finally, leukaemias and lymphomas arise from the 
blood forming cells and from cells of the immune system respectively (Cooper GM, 
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2000). Of these main groupings, carcinomas account for more than 85% of all new 
cases in the UK (Cancer Research, 2020).  
 
Cancers can be further classified according to location, or primary site. In the UK 
prostate, lung, and colon cancer account for over half (53%) of new cases of cancer 
in men, with breast, lung and colon cancer being the most common in women 
(Cancer Research, 2020). To demonstrate the magnitude of this clinical burden, 
42,300 new cases of colon cancer are diagnosed each year in the UK (Cancer 
Research, 2020). 
1.5.2 Risk factors 
The lifetime risk of being diagnosed with cancer in the UK is estimated to be 1 in 2 
for individuals born after 1960 (Cancer Research, 2020). Increasing age is one of the 
most important risk factors for developing cancer, with three quarters of all cancers 
in the UK being diagnosed in those aged over 60, and a third diagnosed in those 
aged over 75 (Macdonald et al., 2018).  
 
The link between cancer and ageing is perhaps unsurprising since both can be 
regarded as different manifestations of the same underlying process. As previously 
discussed, it is the time dependant accumulation of cellular damage that is 
considered to be the cause of chronological ageing and it is this cellular damage 
that, on occasions, can provide advantages to certain cells that eventually results in 
cancer (López-Otín et al., 2013). In under 10% of cancer patients, there is an 
inherited component that predisposes an individual to developing cancer, often at a 
much younger age than seen in non-inherited cancers (Gatalica et al., 2017). In 
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these cases, the individual has a mutation in a cancer predisposition gene that 
provides an early start in tumour development since the mutation is present in every 
cell (Gatalica et al., 2017). Examples of genetic mutations linked to inherited forms of 
cancer include BRCA, causing breast and ovarian cancer, and APC, resulting in 
familial adenomatous polyposis and colon cancer (Kupfer & Ellis, 2016).  
 
Although growing older is unavoidable, the development of cancer is not an 
inevitable consequence of ageing, it is coincidentally associated with preventable 
chronic conditions, avoidable exposures and modifiable risk factors that are all linked 
to increasing the risk of developing cancer (White et al., 2014). It is estimated that 
30% of cancers worldwide and 1 in 4 cancers in the UK are preventable (Cancer 
Research, 2020). Tobacco smoking is the leading cause of cancer in the UK and is 
linked to the development of multiple different forms of cancer including lung, 
oropharyngeal and bladder cancer (White et al., 2014). Other modifiable risk factors 
for cancer development include alcohol consumption (Thun et al., 1997), the 
presence of chronic health conditions (many of which are associated with advancing 
age, such as diabetes) (Epping-Jordan et al., 2005), obesity (Calle et al., 2003), 
excessive sun exposure (C. J. Stein & Colditz, 2004), infections such as HIV, 
hepatitis and HPV (Murthy & Mathew, 2004), and occupational and environmental 
factors, such as asbestos (Stewart & Wild, 2014). 
1.5.3 Treatment options  
Surgical resection has been the cornerstone in the treatment of solid cancer for more 
than 100 years (Reed, 2009) and is achieved through either an open incision, or by 
the use of minimally invasive techniques, such as laparoscopy or robotic assisted 
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surgery. The suitability of a patients with cancer having surgery is dependent on 
several factors. One of the most important considerations is the stage of the cancer, 
which relates to both the size and spread of the disease (Brierley et al., 2016). 
Briefly, cancer staging is based on the TNM (tumour, nodes and metastases) 
classification first developed in Paris in the 1940’s by Pierre Denoix and the Union 
for International Cancer Control (Brierley et al., 2016). In the classification, T 
describes the extent of the primary tumour, either by size or depth of invasion, whilst 
N indicates the absence or presence of regional lymph node metastasis, and M 
indicates the presence or absence of distant metastasis (Brierley et al., 2016). By 
recording the stage of the cancer at presentation, members of the clinical team can 
apply evidence-based treatment guidelines in order to provide the most appropriate 
management for the patient. In general, the lower the staging the more appropriate 
the patient is for surgical resection. This is demonstrated by data from 2013-2014 
showing that of the 45% of patients with solid tumours who underwent surgical 
resection, 69.7% had stage 1 disease compared to just 12.9% of those with the most 
advanced stage, stage 4 (NCRAS, 2020).  
 
The location of the cancer, age, general health of the patient, national treatment 
guidelines and patient preferences are all other considerations when deciding if 
surgery is indicated as a treatment option, with risk-benefit analysis forming the basis 
of these decisions. Although surgery can be used as definitive treatment, it is 
common practice for it to be used in combination with neo-adjuvant and adjuvant 
therapies, such as radiotherapy and chemotherapy, in order to improve survival 
outcomes (Drake et al., 2019; Iwashyna & Lamont, 2002). Figure 4 shows that the 
utility of surgical treatment (alone or in combination with other treatments) declines 
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with age whilst other care, such as targeting symptoms, being used instead. .This is 
often because the risk of surgery outweighs the benefits (G. L. Smith & Smith, 2014) 
 
Figure 4 – Summary of differing treatment options and combinations for patients diagnosed with cancer between 
2013 – 2016 based on age (NCRAS, 2020). 
 
The therapeutic potential of radiation occurred shortly after the discovery of X-rays in 
1895 (Gianfaldoni et al., 2017), with doctors initially using it to treat skin conditions 
such as lupus (Kassabian, 1908). It is now estimated that over half of all patients 
with cancer will have some form of radiotherapy included in their treatment 
(American Cancer Society, 2020). Radiotherapy works by using localised, high 
energy ionising radiation to damage the DNA within cells. Since rapidly proliferating 
cancer cells are more sensitive than normal cells to DNA damage, radiotherapy 
allows targeted treatment for solid tumours whilst minimising toxic effects on 
surrounding healthy tissue (Formenti & Demaria, 2009). Radiotherapy can be 
administered for several reasons. It can be used in conjunction with other treatment 
modalities where achieving curative intent is the aim, or as a palliative treatment in 




Radiotherapy and surgery formed the basis for solid tumour treatment well into the 
1960’s (Arruebo et al., 2011) however despite increasingly radical local treatments, 
cure rates plateaued at about 33% (DeVita & Chu, 2008). This was thought to be 
due to the inability of surgery or radiotherapy to address the distant spread, or 
metastasis, of the cancer. This limitation in the curative capability of these treatments 
paved the way for a greater use of a third type of treatment, chemotherapy. 
 
The term chemotherapy was first coined by German chemist Paul Ehrlich in the early 
1900’s who defined it as ‘the use of chemicals to treat disease’ (DeVita & Chu, 
2008). Chemotherapy was introduced as a method to treat cancer in the 1940s with 
nitrogen mustards and antifolate drugs the first agents to be trialled (Chabner & 
Roberts, 2005). Chemotherapeutic agents prevent the division of rapidly dividing 
cells, such as cancer cells, by interrupting different parts of the cell cycle 
(Bagnyukova et al., 2010). Due to the drug being circulated in the bloodstream, it can 
target cancer cells almost anywhere in the body and has been shown to reduce 
incidence of both local and systemic recurrence along with improve overall survival 
(DeVita & Chu, 2008). Unfortunately, chemotherapy cannot differentiate between 
cancer cells and other rapidly dividing cells such as hair follicles, bone marrow and 
cells within the intestines. This can result in a number of side effects including 
fatigue, diarrhoea and constipation being reported by patients undergoing the 
treatment (Pearce et al., 2017). 
 
Systemic treatment, such as chemotherapy, are considered most effective when 
used as an adjunct to local control measures, specifically surgery and radiotherapy 
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(Nicolaides et al., 2017). For example, downsizing of rectal tumours is seen in most 
patients who undergo neoadjuvant chemoradiotherapy, with complete response 
occurring in 15 – 20% (Dekker et al., 2019). The combination of treatment 
modalities, advances in technology and developments in research has seen survival 
from cancer steadily increase over the past 50 years, with the biggest observed 
changes being seen in colon, Non-Hodgkin’s lymphoma and rectal cancer 
(Macmillan Cancer Support, 2012). This is illustrated by data from England and 
Wales showing that all cancer survival index at 1 year was 50% in 1970 yet had 
increased to 69% by 2011 (Quaresma et al., 2015).  
1.5.4 Socioeconomic impact  
Additional to the physical and psychological burden of cancer for sufferers and their 
support networks, cancer is financially expensive. The cost of cancer on the UK 
economy is thought to exceed £1.4 billion through lost productivity alone, with this 
figure increasing to £7.6 billion when mortality is taken into account (Hilhorst & 
Lockey, 2019). NHS England places annual expenditure on cancer diagnosis and 
treatment at £5.68 billion, amounting to 5% of total health expenditure (Jönsson & 
Hofmarcher, 2017). There are also significant financial implications to the individual 
and their families following diagnosis, with many having to adjust their working lives 
to fit around treatment. Research has showed that cancer patients were found to be, 
on average, £570 worse off per month following their diagnosis (Wind-Cowie & 
Salter, 2013), with this financial impact being more apparent in those diagnosed 




Figure 5 – The impact cancer has on financial health of individuals depending on the age at diagnosis (Hilhorst & 
Lockey, 2019) 
 
1.5.5 Emotional impact 
Regardless of the prognosis, a cancer diagnosis causes some degree of emotional 
distress, anxiety and depression for both the patient and their family (Woźniak & 
Izycki, 2014). In certain types of cancer, patients can also experience feelings of guilt 
associated with ‘risky’ behavioural traits such as smoking, which can add to the 
emotional distress (LoConte et al., 2008). The impact on mental well-being can result 
in patients finding it harder to cope with their treatment and any side effects 
(Sharma, 2020). Linked to this, depression has also been shown to result in higher 
rates of mortality, with patients who show even a few depressive symptoms being at 




A cancer diagnosis affects a multitude of people connected to an individual with 
cancer. More than three in four patients describe the impact of cancer on family life 
as very or moderately negative, and two thirds believe the diagnosis had had a 
negative impact on their family’s social life (Hilhorst & Lockey, 2019). Additionally, 
with more and more people surviving cancer, long term side effects and disability 
can affect the mental wellbeing of individuals and their families for many years after 
treatments (K. D. Stein et al., 2008). 
1.6 Cancer cachexia 
Many patients with cancer experience muscle wasting and weakness (Morishita et 
al., 2017). This can be caused by sarcopenia or by cancer cachexia, a multifactorial 
syndrome characterised by an ongoing loss of skeletal muscle mass, with or without 
loss of adipose tissue, that cannot be fully reversed with conventional nutritional 
support (Shum et al., 2018). Although cachexia and sarcopenia share some 
pathological mechanisms, cachexia is characterised by an energy imbalance, 
resulting from decreased nutritional intake and increased energy expenditure caused 
by a hypermetabolic state (Argilés et al., 2015). The often results in significant weight 
loss, a feature that is absent in in sarcopenia (Evans et al., 2008; Porporato, 2016). 
Although skeletal muscle is the main tissue involved, cachexia also affects multiple 
other organs including the brain, liver, gut and heart (Argilés et al., 2014). 
 
The severity of cachexia is difficult to assess objectively, with cachexia being seen 
as a continuum through three clinically relevant stages as described in Figure 6. Not 
all patients transverse the entire spectrum, with the risk of progression dependent on 
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factors such as the cancer type and stage, degree of systemic inflammation, low 
food intake and lack of response to anticancer therapy (Fearon et al., 2011). 
 
Figure 6 – Stages of cancer cachexia (Fearon et al., 2011) 
 
1.6.1 Cachexia and cancer treatment 
Cachexia is directly associated with cancer patient morbidity and mortality (Carson et 
al., 2016) and although not associated with all cancer types, cachexia is thought to 
affect 50 – 80% of cancer patients and is reported to be indirectly responsible for at 
least 20% of all cancer deaths (Penna et al., 2019). Patients that exhibit cancer 
cachexia have increased fatigue and decreased functional independence prior to 
and during treatment, and this has an impact on the success of the interventions 
used (Vanderveen et al., 2017).  
 
Resectional surgery places profound metabolic and cardiorespiratory stresses on the 
body (Boereboom et al., 2016), and a number of studies have shown that patients 
with low skeletal muscle mass and density are at an increased risk of post-operative 
complications, mortality and increased length of hospital stay (M. H. Choi et al., 
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2018; van Vugt et al., 2018). Similarly, in regards to the use of systemic treatment 
such as chemotherapy, treatment plans are often compromised by cachexia, with 
affected individuals requiring dose limitations and even therapy interruptions, 
resulting in a reduction in drug efficacy and patient survival odds (Penna et al., 
2019). 
 
Similar to the treatment of sarcopenia, physical exercise has been shown to be 
effective in improving physical function and quality of life (Morishita et al., 2017). 
Studies have shown that EET improves muscle wasting in cardiac and cancer 
patients (Alves et al., 2015), with RET being shown to attenuate muscle wasting 
associated with a variety of catabolic conditions including cancer (Al-Majid & 
Mccarthy, 2001). Additionally, the combination of EET and RET has been found to 
improve upper and lower body strength more effectively when compared to usual 
care in patients with cancer (Stene et al., 2013). Despite this however, and as seen 
with age related sarcopenia, no intervention has been found to completely reverse 
cachexia (V. E. Baracos et al., 2018). 
1.6.2 Cachexia and skeletal muscle function 
As with sarcopenia, the skeletal muscle phenotype in cancer cachexia is 
characterised by a reduced number of mitochondria and decreased expression of 
regulatory factors involved in mitochondrial biogenesis (Antunes et al., 2014). Similar 
to that seen in ageing, an increase in ROS levels could, in part, explain the changes 
seen in mitochondrial function (van der Ende et al., 2018). Additionally, pre-clinical 
animal models have demonstrated an upregulation in proteins responsible for 
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initiating mitophagy as well as negatively affecting biogenesis (van der Ende et al., 
2018).  
 
Systemic inflammation is recognised as a hallmark of cancer cachexia with 
circulating cytokines established initiators of skeletal muscle wasting as well as 
mitochondrial dysfunction (Carson et al., 2016; Vanderveen et al., 2017).  
Inflammatory mediators are released from both the tumour cells themselves, and 
from cells within the tumour microenvironment including the hosts own immune cells 
(V. E. Baracos et al., 2018). The presence of these mediators are thought to induce 
an imbalance between protein synthesis and degradation in muscle fibres (Antunes 
et al., 2014). Specific to cancer cachexia, three cytokines have been implicated. 
Firstly, IL-6 has been shown to effect skeletal muscle metabolism and is considered 
a prime regulator of the acute phase response seen in cachexia (Laine et al., 2013). 
Secondly, TNF has long been associated with muscle pathology and is thought to 
alter levels of circulating hormones required for muscle growth, as well as stimulate 
further catabolic cytokines that contribute to anorexia (Argilés et al., 2011). Finally 
myostatin, which is known to play a crucial role in the negative regulation of skeletal 
muscle growth and differentiation, has been found to be upregulated in cancer 
(Elkina et al., 2011) 
 
To date, there is limited knowledge as to the underlying pathways responsible for the 
role mitochondrial dysfunction plays in cancer cachexia and whether it can be 
prevented with the similar proposed in the treatment of sarcopenia.  
 
 31 
1.6.3 The use of exercise in cancer treatment 
Exercise is traditionally classed as either endurance, aerobic/resistance, or strength 
training, with each modality associated with distinct physiological adaptations. EET is 
associated with an improved capacity for aerobic energy metabolism and fatigue 
resistance and is the most effective approach for improving CRF (Lin et al., 2015) 
whilst RET is linked to muscle hypertrophy and increased force generating capacity 
(Whyte, 2006). In recent years, there has been considerable interest surrounding 
high-intensity interval training (HIIT), with claims to induce health benefits of a 
similar, if not superior magnitude to moderate- intensity continuous exercise 
(Cassidy et al., 2017). Traditionally used in an elite athletic training setting, and 
performed at supra-maximal intensities (Gibala & Little, 2020), HIIT can be simply 
defined as intermittent periods of intense exercise with periods of recovery that can 
elicit adaptions resembling both endurance and strength training (MacInnis & Gibala, 
2017). In addition, at a lower relative intensity than those used by athletic 
populations, HIIT has been shown to be a time efficient (Gibala et al., 2006), 
tolerable (Cassidy et al., 2016) and largely enjoyable (J. E. M. Blackwell et al., 2020) 
regime when used in a variety of clinical cohorts, including those with chronic 
disease and cancer (Cassidy et al., 2017; Loughney et al., 2015). 
 
The preoperative status of the patient is now viewed as an increasingly important 
factor for improving postoperative outcomes. The practice of prehabilitation is 
becoming more prevalent in the preoperative workup of high risk patients, with the 
main aim directed at enhancing the patient’s functional capacity before surgery 
(Banugo & Amoako, 2017). In broad terms, surgical prehabilitation is described as ‘a 
strategy to address modifiable risk factors that impact treatment outcomes’, with the 
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theory behind it suggesting that  by increasing the functional capacity prior to 
surgery, a prehabilitated patient will retain a higher level of functional ability and 
recovers more rapidly in the perioperative period compared with a non-prehabilitated 
patient (Francesco Carli et al., 2017; Franco Carli & Zavorsky, 2005) (Figure 7). 
 
 
Over the past few years, several studies have evaluated the use of prehabilitation to 
improve physical function to overcome surgical stress and improve postoperative 
recovery time (Piraux et al., 2018). To date, prehabilitation regimes have had varying 
success, with some showing a meaningful benefit (Moran et al., 2016; Wang et al., 
2016), while others have failed to elicit meaningful benefit in physiological 
parameters (Boereboom et al., 2019). In addition, the variation in prehabilitation 
regimes makes their efficacy difficult to conclude upon. For example, some regimes 
focused on a single target, such as nutrition (Braga et al., 2009), lifestyle and 
psychological support (Johnston & Vogele, 1993) or smoking cessation (Thomsen et 
al., 2014), while others were multi-modal (F. Carli et al., 2010; Li et al., 2013).  
 
Figure 7 – Conceptual model depicting the theoretical benefits of prehabilitation  
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Exercise based prehabilitation programs have been shown to enhance muscle 
protein synthesis (MPS) (Smeuninx et al., 2021), improve mitochondrial function 
(Seo et al., 2016) and modulate the levels of inflammatory cytokines in patients with 
cancer (Antunes et al., 2014). The effects of prehabilitation in patients with cancer 
was first reviewed by Loughney et al., who found significant improvements in 
physical fitness but the effect on other outcomes, such as quality of life and fatigue 
were inconclusive (Loughney et al., 2016). Despite such positive findings, it is 
generally agreed that existing studies must be viewed with a degree of caution since 
pooling data is difficult given the heterogeneity of the study population (Banugo & 
Amoako, 2017).  
 
The use of prehabilitation as part of the cancer treatment pathway faces many 
challenges. For example, in the UK, the National Cancer Action Team specifies that 
treatment should start within 31 days of the decision to treat (NCIN, 2010). As a 
result, many of the traditional exercise training programs fail to significantly improve 
CRF or other markers of physical function in that timeframe (Boereboom et al., 
2019).  Additionally, there are issues implementing a training program that can 
achieve adherence, and therefore positive results, in for a patient cohort that is prone 
to suffer high levels of fatigue (Eng et al., 2018; Fernandez et al., 2015).  
 
Despite these challenges, studies have shown that an exercise training within this 31 
day decision to treat program does have the potential to improve a patients CRF 
(Boereboom et al., 2016), and as such improve their post-surgical clinical outcomes 
(Moran et al., 2016). This finding does not appear to be uniform across all cancer 
types, with work from our group showing that a single HIIT protocol, shown to be 
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effective in healthy older adults, was able to improve the CRF of patients with 
prostate cancer (J. E. M. Blackwell et al., 2020), but not those with colorectal cancer 
(Boereboom et al., 2019) To date, there is little research exploring the relationship 
between CRF and mitochondrial content and function. A better understanding of this 
relationship in health, and in cancer, may help is understand the potential of 
prehabilitation in different cancer groups.  
1.7 Research synopsis 
Based on the available evidence presented in this chapter, we highlight the 
importance of skeletal muscle and its mitochondria for whole body health in both 
ageing and cancer. This thesis will firstly aim to systematically review the available 
literature exploring the link between pre-existing sarcopenia and clinical outcomes 
associated with individuals with locally advanced colorectal cancer. Following this, 
we will present data from a healthy volunteer study which seeks to determine the 
relationship between skeletal muscle mitochondrial activity and measures of physical 
function across the life course. Finally, we will put forward the rationale and 
experimental workplan for possible further research that could help establish 
differences in physical fitness and mitochondrial activity in those with different forms 
of cancer. 
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2 The prognostic significance of pre-existing sarcopenia 
in patients with locally advanced rectal cancer 
undergoing neoadjuvant chemotherapy prior to surgical 
resection: a systematic review and meta-analysis. 
2.1  Chapter focus 
In the previous chapter, we explored the link between sarcopenia and adverse health 
outcomes, such as post-operative complications and increased length of hospital 
stay. It is becoming increasingly apparent that the body composition and nutritional 
status of patients with cancer at the time of diagnosis plays a substantial role in 
predicting both short- and long-term clinical outcomes. In this chapter, we will review 
the prognostic significance sarcopenia has on the clinical outcomes of patients with 
locally advanced rectal cancer who undergo neoadjuvant chemotherapy prior to 
surgical resection.  
  





Colorectal cancer (CRC) is the third leading cause of cancer deaths and fourth most 
commonly diagnosed cancer in the world (Rawla et al., 2019). In the UK, the largest 
proportion of bowel cancer cases occur in the rectum, accounting for 31.5% and 
23.1% of cases in males and females respectively (Cancer Research, 2020). 
Surgery is the gold standard treatment for people with rectal cancer provided the 
tumour is deemed resectable (National Institute for Health and Care Excellence, 
2020). In patients who have locally advanced rectal cancer, those that undergo 
neoadjuvant chemoradiotherapy (nCRT) have been found to have less local 
recurrence and better overall and disease free survival (National Institute for Health 
and Care Excellence, 2020). Other advantages of nCRT include decreasing tumour 
volume and enhancing the probability of anal sphincter preservation (Park et al., 
2018). Treatment with nCRT also introduces the chance of complete pathological 
response, with a R0 resection being recorded in up to 15 - 20% of cases (Dekker et 
al., 2019). 
 
It is becoming increasingly apparent that the body composition and nutritional status 
play an important role in predicting both short and long term outcomes in cancer 
patients (V. Baracos & Kazemi-Bajestani, 2013). In recent years, low skeletal muscle 
mass has been shown to be a negative prognostic indicator in malignant diseases of 
the lungs and gastrointestinal tract (Levolger et al., 2015; Martin et al., 2013). 
Specific to CRC, reduced muscle mass and increased visceral fat mass has been 
shown to be negative prognostic factors (Bardou et al., 2013; Gibson et al., 2015; C. 
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M. Prado et al., 2008). Similarly, an association between low skeletal muscle mass 
and short term outcomes such as length of stay (LOS) and infection rate has been 
shown in patients with CRC or colorectal liver metastasis (Lieffers et al., 2012; Peng 
et al., 2011; van Vugt et al., 2018).  
 
Low skeletal muscle mass in cancer patients is multifactorial with both modifiable 
and non-modifiable features. Both chemotherapy and radiotherapy have well known 
side effects that include nausea, vomiting and anorexia, which can all result in a 
more rapid loss of muscle mass in cancer patients (Oflazoglu et al., 2020). Studies 
have also shown a relationship between the degree of muscle loss suffered by an 
individual and factors including the duration of treatment and the type of cancer 
(Oflazoglu et al., 2020; Yamaoka et al., 2015), however these are often in patients 
with advanced or metastatic disease. When looking at patients with resectable 
disease, Eriksson et al. showed that skeletal muscle mass decreased during nCRT 
for CRC liver metastasis, with those being sarcopenic preoperatively having a poorer 
overall survival (Eriksson et al., 2017). What is lacking in current literature is the 
impact neoadjuvant CRT (nCRT) has on the prognosis of patients with pre-existing 
sarcopenia.  
2.2.2 Defining sarcopenia 
Sarcopenia is characterised by the progressive and generalised loss of muscle mass 
and function. In 2010, the European Working Group on Sarcopenia in Older People 
(EWGSOP) agreed a consensus definition of ‘the loss of muscle mass with loss of 
muscle function (strength or physical performance), with measurements two 
Standard Deviations (SD) below the mean of a young reference population’ (Cruz-
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Jentoft et al., 2010). Despite this, defining sarcopenia remains controversial and 
there are multiple definitions published within the literature.  
 
The most commonly used cut off values to diagnose sarcopenia were first described 
by Prado et al. who used optimum stratification analysis between low muscle mass 
and mortality in a population of 250 obese Canadians with respiratory or GI 
malignancies (C. M. Prado et al., 2008). Although these values of 52.4 cm2/m2 for 
males, and 38.5 cm2/m2 for females considers the gender of the individual, they fail 
to account for other demographic factors such as ethnicity, body size, lifestyles and 
cultural background and this has led to differences in reported definitions (L. K. Chen 
et al., 2014).  
 
More recently, due to an increased understanding of sarcopenia, the EWGSOP 
recommended that muscle strength, rather than mass, be the primary parameter of 
sarcopenia, due to it being shown to be better at predicting adverse outcomes (Cruz-
Jentoft et al., 2019). This is because, although muscle mass and strength are related 
to one another, their trajectories of decline are not linear, with muscle strength 
declining much faster than mass (Goodpaster et al., 2006). There are several well 
validated tools for the assessment of muscle strength, such as hand grip strength 
(HGS) (Aadahl et al., 2011), lower limb muscle strength (Bohannon et al., 2012) and 
sit to stand test (Freire et al., 2012; Gómez Montes et al., 2013). Although these 
assessment tools are used in the research setting, their use in wider clinical practice 
is not always feasible with many suiting the secondary care setting rather than 
primary care (Beaudart et al., 2016).  This limits any proposed definition of 
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sarcopenia being universally adopted, with the main parameter remaining body 
composition and muscle mass in the clinical setting. 
2.2.3 Measuring body composition 
A wide range of techniques can be used to quantify body composition with cost, 
availability and ease of use determining which technique is applied in specific 
settings. Anthropometric methods such as body mass index (BMI), calf 
circumference, mid upper arm circumference and skinfold thickness are all simple 
clinical tools which can estimate body composition (S. Yu et al., 2015). However, due 
to large predictor error and the lack of universally agreed cut off points, the validity of 
anthropometric methods on their own are of limited worth (Beaudart et al., 2016).  
 
Dual-energy x-ray absorptiometry (DXA) is a well-established, low radiation 
technique used to assess body composition in both the clinical and research setting. 
Clinically, DXA is primarily used to diagnose osteoporosis, however it can also 
provide reproducible estimates of appendicular skeletal lean mass (ALM) by 
measuring the sum of the non-bone and non-fat mass of the four limbs (Levine et al., 
2000). The ALM is then adjusted for body size to generate skeletal muscle index 
(SMI), which can be used to produce gender specific cut off points to diagnose 
sarcopenia (Beaudart et al., 2016). Limitations to DXA include its inability to assess 
other body components such as intramuscular fat, it’s failure to provide information 
on muscle quality and its inaccuracy when assessing muscle mass in people of 
varying age (Erlandson et al., 2016).  
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Bio-electrical impedance analysis (BIA) is another method used to estimate total or 
ALM. BIA does not measure muscle mass directly, instead provides an estimation of 
muscle mass based on whole body resistance to an electrical current (Cruz-Jentoft 
et al., 2019). Lean tissue supplies the least resistance to the current because of its 
high water content, with the speed of the current being converted to estimate body 
fat percentage and fat free mass (Esco et al., 2015). Although inexpensive and easy 
to use in clinical practice, the method is seen as less accurate than other methods 
available due to its dependence on the hydration status of the individual, and tends 
to overestimate muscle mass and underestimate fat mass (Esco et al., 2015; Reiss 
et al., 2016).  
 
Computed tomography (CT) and magnetic resonance imaging (MRI) are considered 
to be the gold standard and most accurate imaging methods for quantifying muscle 
mass, muscle cross sectional area and muscle quality (Mitsiopoulos et al., 1998). 
MRI Is based on the magnetic properties of hydrogen protons, which constitute a 
large portion of body tissue. Unlike either DXA or CT, direct visualisation of MR 
images allows for quantification of muscle and fat volumes from body segments and 
individual muscle groups (Erlandson et al., 2016). The main disadvantage to MRI 
use is the limited access to the device and the requirement for highly trained 
individuals to perform and interpret the images. There are also several 
contraindications, such as pacemakers and other magnetic implants, along with the 
requirements for the individual to maintain a prolonged supine position (Erlandson et 
al., 2016). This can limit its use in the older population in which sarcopenia is more 
prevalent. 
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Cross sectional abdominal CT scans provide a precise measure of overall muscle 
mass through the assessment of core muscle size. Core muscle size can be 
measured as either the psoas area or total skeletal muscle at specific levels of the 
scan. Most researchers use consistent methods for CT image analysis focusing on 
3rd lumbar vertebrae (L3) as the standard bony landmark (Kazemi-Bajestani et al., 
2016). This is due to evidence suggesting the best correlation between core muscle 
size and total muscle mass was 5 cm above L4/L5 vertebral level (C. M. M. Prado et 
al., 2009; Shen et al., 2004). More recently, it has been suggested that calculation of 
psoas density may be a more accurate method of determining sarcopenia than 
psoas area as variable fat content in skeletal muscle may increase the cross 
sectional area, therefore confounding the measurement of lean muscle area (Herrod 
et al., 2019). 
 
Since CT imaging is expensive, requires specialist interpretation and exposes the 
individual to a small amount of radiation, it is not recommended as a routine method 
for assessing body composition (Gibson et al., 2015). In the case of patients with 
cancer however, CT scans are used routinely in the diagnosis and staging process 
of their treatment. This has led to them being the most frequently used modality in 
research papers to analyse body composition in cancer patients. 
2.2.4 Aim 
The aim of this review is to examine the relationship between pre-existing 
sarcopenia and the prognostic outcomes in patients with locally advanced CRC who 
underwent nCRT prior to resectional surgery. The primary outcome was overall 
survival (OS), with disease free survival (DFS) being a secondary outcome.  




2.3.1  Study design 
The systematic review was registered with PROSPERO prior to the literature search 
(registration number CRD42019157313) and carried out in accordance with the 
PRISMA statement (Moher et al., 2009). Any comparative study relating to the 
prognostic outcomes of sarcopenic versus non-sarcopenic patients diagnosed with 
LARC who received nCRT prior to resectable surgery were included. Exclusion 
criteria included any study in which the cohort included patients with irresectable, or 
advanced/metastatic colorectal cancer, combined outcomes of different types of 
cancer or treatment modalities, such as pre- and post-operative chemotherapy, or 
introduced interventions preventing muscle loss during the treatment pathway. 
2.3.2 Literature search 
A trained Clinical Research Librarian performed the literature search using MEDLINE 
and EMBASE databases. There was no language or date restriction, and the 
databases were searched from inception until 14th December 2020. The Cochrane 
library of systematic reviews was searched for previous reviews, whilst 
clinicaltrials.gov was searched for any unpublished studies. Systematic reviews of 
similar topics were searched for any relevant previous studies specific to locally 
advanced colorectal cancer.  
 
Medical subject headings (MeSH) included the terms ‘COLORECTAL TUMOR’, 
‘NEOADJUVANT THERAPY’, TREATMENT OUTCOME and ‘PROGNOSIS’. Free 
text words included ‘chemoradiotherapy’, ‘sarcopenia’ and ‘muscle mass’. Example 
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of the full search strategy can be found in Appendix A. Abstracts were independently 
screened by two authors (JH and TS) using the Rayyan systematic review software 
(2016, Qatar Computing Research Institute, Doha, Qatar) (Ouzzani et al., 2016). If 
either author deemed the abstract potentially relevant, it was then considered for full 
text review. Full text versions were independently screened against the inclusion and 
exclusion criteria by two authors (JH and TS). All discrepancies between studies 
were resolved by consensus.  
2.3.3  Data extraction 
Study characteristics including author, year of publication, mean/median age (years), 
percentage of male individuals, percentage defined as sarcopenic at baseline (%), 
Follow up (months), and gender specific cut of values used for defining sarcopenia 
(cm2/m2)) were extracted by one author (JH). Outcome data (OS and DFS) were 
independently extracted by two authors (JH and TS). When outcome data was not 
shown in the correct format, the corresponding author of the study was contacted via 
email and the data was requested. The Risk Of Bias In Non-randomised Studies – of 
Interventions (ROBINS-I) tool for assessing bias was used to measure risk of bias for 
included study. Risk of bias was performed independently by two authors (JH and 
EH), with any disagreement being resolved by consensus of a third-party author 
(TS). 
2.3.4  Statistical analysis 
We performed meta-analysis on reported hazard ratios (HR) and 95% confidence 
intervals (CI) using DerSimonian–Laird random-effects models. These were 
converted to logHR, and standard errors were calculated from 95% CI. Where 
possible, we used the multivariate HR where reported. We aimed to conduct 
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investigation of heterogeneity and publication bias although there were too few 
included studies. Statistical heterogeneity was assessed using the I2 statistic, with 
values above 50% taken as evidence of statistical heterogenicity. GRADE was used 
to assess the certainty of evidence. All analyses were conducted on Stata Version 
16. 
2.4  Results 
2.4.1 Search results 
The primary search strategy produced a total of 1117 results including 87 duplicate 
studies. Of these, 1016 were excluded as not being relevant. This left 14 studies for 
full text review. From this, 5 studies were deemed suitable for inclusion for analysis. 
Figure 8 summarises the search results. 
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 Figure 8 – PRISMA flowchart 
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2.4.2  Study characteristics 
Characteristics of the included studies, which comprised of a total of 598 patients, 
can be found in Table 1. The earliest study that met the inclusion criteria was 2017, 
with the latest being 2020.  All papers were published as journal articles in peer 
reviewed journals. All included studies were retrospective cohort studies.  
2.4.3 Risk of Bias 
Risk of bias was assessed using the ROBINS-I tool (Table 2). Four studies were 
considered moderate risk of bias regarding confounding factors since patients of 
different age, cancer stage and comorbidities were included. One study was 
considered high risk of bias in this category as it failed to perform multivariable 
statistical adjustment due to the small number of patients. Four studies were deemed 
moderate risk of bias in missing data since they excluded patients who, despite 
meeting the criteria for inclusion, did not have the appropriate imaging pre and post 
chemoradiotherapy. All five studies were judged to have moderate risk of bias in 
relation to measurement of outcomes since they were all retrospective, non-blinded 
studies. Two studies were deemed to be at moderate risk of bias in relation to 
reporting results, one reporting results of a subgroups of the total cohort whilst the 
other dividing the cohort into quartiles to report findings. 
 
Overall, one study was deemed to be at severe risk of bias, with the remaining four 
studies considered at moderate risk.  
 




Table 1 – Summary of patient characteristics 
N – number, NR - not reported, a mean or median as published, b cm 
  
Author Year Country N Age a % male 
Sarcopenia at 
baseline (%) 
Follow up (months) 
Sarcopenia cut off 
point, male b 
Sarcopenia cut off 
point, female b 
Choi et al. 2018 South Korea 188 61.3 (27 – 84) 62.2 39.34 52 (5 – 91) ≤52.4 ≤38.5 
Chung et al. 2019 South Korea 93 NR 64.5 51.6 NR ≤52.4 ≤38.5 
De Nardi et al. 2019 Italy 52 63 (32 – 79) 65 59.6 56 (32 – 83) ≤52 ≤42 
Levolger et al. 2017 Netherlands 121 61 (53 – 66.3) 58.2 NR 41 (26 – 62) ≤52.4 ≤38.5 
Takeda et al. 2018 Japan 144 62.5 (32 – 75) 70.8 25.7 67.6 (5.7 – 137.1) ≤45 ≤33.8 

















Missing Data Measurement of 
Outcomes 
Reported Result Overall 
Choi et al. (2018) Moderate Low Low Low Moderate Moderate Low Moderate 
Chung et al. (2019) Moderate Low Low Low Moderate Moderate Moderate Moderate 
De Nardi et al. (2019) Severe Low Low Low Low Moderate Moderate Severe 
Levolger et al. (2017) Moderate Low Low Low Moderate Moderate Low Moderate 
Takeda et al. (2018) Moderate Low Low Low Moderate Moderate Low Moderate 
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2.4.4 Data synthesis 
Four studies reported OS, whilst 3 studies reported DFS within the paper itself. A 
further study was able to provide data relating to OS and DFS for patients with pre-
existing sarcopenia following correspondence with the lead author. 
2.4.5  Overall survival (OS) 
A total of 598 patients from 5 studies were included in the analysis of hazard ratios 
for OS. All papers were comparative cohort studies. Hazard ratios were extracted 
from multivariate analysis in 2 studies and univariate analysis in 3 studies. Meta 
regression analysis, assessing the relationship between pre-existing sarcopenia and 
a poorer overall survival, showed a significant association (pooled HR 1.69, 95% CI: 
1.15, 2.48) (Figure 9). There was low statistical heterogeneity (I2 = 19.15%).  
 
Figure 9 – Forest plot showing meta-analysis of the association between pre-existing sarcopenia and OS in 
patients with LARC. 
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2.4.6  Disease free survival (DFS) 
A total of 4 studies comprising of 505 patients were available for analysis of HRs for 
DFS. Hazard ratios were extracted from multivariate analysis in 1 study and 
univariate analysis in 3 studies. All papers were comparative cohort studies. Meta 
regression analysis, assessing the relationship between pre-existing sarcopenia and 
a shorter DFS appeared to show an association, however this was not statistically 
significant (pooled HR 1.07, 95% CI 0.63, 1.82) (Figure 10). Heterogeneity between 
studies was moderate/high (I2 = 56.05%).  
 
Figure 10 - Forest plot showing meta-analysis of the association between pre-existing sarcopenia and DFS in 
patients with LARC. 
 
2.5 Discussion 
Over the past decade, there has been significant intertest in the link between 
sarcopenia and prognostic outcomes in cancer treatment. To our knowledge this 
review is the first to evaluate the relationship between pre-existing sarcopenia and 
prognostic outcomes of patients with LARC who underwent both neoadjuvant 
chemotherapy and resectional surgery.  
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There was a significant association between pre-existing sarcopenia and poorer OS. 
This finding is in line with other studies that looked at patients who underwent 
curative resection of colorectal cancer and colorectal liver metastasis (Miyamoto et 
al., 2015; Peng et al., 2011), as well as in patients with various solid cancer types 
across different disease stages (Shachar et al., 2016). This indicates that a patient’s 
body composition and muscle mass at the time of diagnosis is an important indicator 
for oncological outcomes.  
 
The relationship between pre-existing sarcopenia and a worse DFS was less clear. 
Although an association was found, it was not significant and there was a high level 
of heterogeneity between the studies. The reasons for this are unclear but likely 
multifactorial. Firstly, cut off values used to define sarcopenia varied between studies 
and, as such patients classed as sarcopenic in one study may not have been 
included in another. Takeda et al. highlighted this by showing that, had they used the 
most common cut off values of 52.4 cm2/m2 for males and 38.5 cm2/m2 for females, 
70.1% of patients in their study would have been classified as sarcopenic rather than 
the 25.7% that were when using their cut off values.  
 
Another possible explanation for the high level of heterogeneity is related to the 
biologic response patients have to the neoadjuvant treatment. Previous studies have 
shown a significant association between the systemic inflammatory response caused 
by the tumour and the degree of muscle mass loss in patients with colorectal cancer 
(Malietzis et al., 2016; Richards et al., 2012). This theory was further supported by 
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Heus et al. who analysed the effect chemoradiation had on preoperative body 
composition of patients with LARC and found there was actually an increase in 
skeletal muscle area following chemoradiotherapy (Heus et al., 2016).  It is therefore 
reasonable to suggest that pre-existing muscle loss resulting from the metabolic and 
inflammatory response caused by the tumour could be, in part, reversed because of 
successful neoadjuvant treatment. This was demonstrated by De Nardi et al who 
found 62.5% of patients who did not respond to nCRT suffered muscle loss of 
greater than 2%, whilst 68.2% of responders showed no muscle decrease. This 
could also explain why, of the 30 patients with pre-existing sarcopenia included in 
the De Nardi et al study, 6 gained muscle mass during neoadjuvant chemotherapy. 
 
As previously mentioned, mitochondrial function plays a vital role in muscle health 
and function and dysfunction of the mitochondrial network is a suggested contributor 
in the development of sarcopenia. Animal models have shown that chemotherapy is 
responsible for the activation of pathways seen in the pathogenesis of sarcopenia 
and that this results in muscle mitochondrial dysfunction and depletion (Penna et al., 
2010; Pin et al., 2018). Additionally, alterations of muscle mitochondrial homeostasis, 
as measured by markers of mitochondrial fusion, fission and biogenesis have been 
displayed in animal models affected by both cancer and exposure to chemotherapy 
(Barreto et al., 2016). This would suggest that cancer patients who have pre-existing 
sarcopenia could be more vulnerable to further losses of mitochondrial function, 
which may exacerbate reductions in muscle function. Cespedes Feliciano et al. 
found that lower muscle mass was associated with higher odds of early treatment 
discontinuation, treatment delay and dose reductions independent of age, sex and 
cancer stage (Cespedes Feliciano et al., 2017), all of which will have an impact on 
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the duration of DFS and, ultimately OS. Although this may in part be related to the 
pharmacokinetics and metabolism of chemotherapy agents, as patients with lower 
muscle mass have smaller tissue volume for distribution of certain chemotherapy 
agents resulting in reduced metabolism and clearance of the drug, leading to greater 
toxicity (Cespedes Feliciano et al., 2017), preserving muscle mitochondrial health 
and function may provide a target to prevent significant muscle loss during 
neoadjuvant treatment. 
 
To date, few studies have looked at the impact a change in body composition during 
neoadjuvant treatment has on those with resectable colorectal cancer. It is now 
suggested that the degree of muscle mass loss during CRT is a more powerful 
prognostic factor than low skeletal muscle mass at a specific point. This was 
highlighted in many of the studies included in the review but since all were 
retrospective, the conclusions drawn were limited. De Nardi et al, Levoger et al and 
Chung et al all showed an association between the degree of skeletal muscle loss 
during neoadjuvant treatment and worse survival outcomes. These findings agree 
with others that looked at both oesophageal and non resectable colon cancer (Awad 
et al., 2012; Järvinen et al., 2018; Miyamoto et al., 2015; Okuno et al., 2019). This 
reenforces the idea that if significant changes in body composition could be 
prevented during neoadjuvant treatment, prognostic outcomes for this cohort of 
patients could be improved. 
 
Despite the mounting evidence relating to poor outcomes and low skeletal muscle 
mass, there is no universally accepted therapy for improving and maintaining muscle 
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mass and in patients with cancer (Okuno et al., 2019). There are also currently no 
accepted nutritional recommendations for individuals with sarcopenia (Beaudart et 
al., 2016). Similarly, although there is an increasing number of studies that show 
physical exercise training programs before major surgery improve cardiorespiratory 
fitness (Berkel et al., 2018; Boereboom et al., 2016; O’Doherty et al., 2013), there is 
no robust evidence to show that prehabilitation increases muscle mass or function. 
This further highlights the complexity of treating sarcopenia and how it is likely that 
no single treatment will be successful in all patients. 
2.5.1 Limitations 
The study has several limitations. Firstly, due to no universally agreed values of SMI 
to define sarcopenia, multiple definitions were included in this study. The cut off used 
to define sarcopenia in females ranged from 33.5 – 42 cm2/m2 and in men from 45 – 
52.4 cm2/m2. This variation when defining sarcopenia is likely to have played a part 
in the degree of heterogeneity seen in the results, especially that of DFS. 
 
Secondly, since all the studies were retrospective, there is risk of bias due to 
confounding factors and absent data. All studies were single centred and had limited 
numbers of patients. This has often prevented multivariable analysis of data to be 
performed. Additionally, there was no measurement of muscle function included. 
With the general consensus suggesting that changes in muscle function play more of 
a role in diagnosing sarcopenia, the conclusions drawn from any retrospective study 
is limited.  
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Finally, with much of the data being collected between 2004 – 2014, most surgical 
resections were open rather than laparoscopic. It is now common practice to follow a 
laparoscopic approach as it is known to carry fewer complications and is associated 
with a shorter hospital stay and quicker return to oral diet (Devoto et al., 2017). 
When considering this in the elderly population, where any significant period of 
muscle inactivity results in muscle loss, the type of surgery could have played a role 
in decreasing OS and DFS.  
 
2.6 Conclusion 
Our meta-analysis shows a strong association between pre-existing sarcopenia and 
poorer OS in patients with LARC who undergo nCRT. Large scale, prospective 
studies looking at the presence of both low SMI and altered muscle function in 
individuals with CRC are required to gain a greater understanding. Additionally, more 
research is required to investigate potential preventative methods, such as nutritional 





3 Exploring the effect chronological age has on global 
physical function and measures of muscle function and 
mitochondrial activity. 
3.1  Chapter focus 
The changes seen in global physical function and measures of muscle function as 
humans age are well established, with these changes seen to have a detrimental 
effect on an individual’s ability to remain healthy and independent. In this chapter. we 
aim to establish the degree of variation in physical and skeletal muscle function in a 
cohort of healthy young and old volunteers, before investigating if skeletal muscle 





It is well established that the ageing process reduces both global physical 
performance and skeletal muscle function (Milanović et al., 2013). Due to the 
complex interplay between age associated reduction in physical activity and the 
intrinsic ageing processes, the aetiology behind this decline is still not fully 
understood.  
 
As previously discussed in Chapter 1, loss of muscle mass is a well characterised, 
and easily measurable end point seen in the ageing process. Although muscle mass 
loss is associated with an increased risk of developing chronic disease and disability, 
an increase in muscle mass does not always translate into an improved level of 
physical performance in the elderly (C. Cooper et al., 2013). It is now thought that 
muscle ‘health’ is better predicted through assessment of muscle strength and power 
(Beaudart et al., 2019), with muscle function measures leading the latest definition of 
sarcopenia from the EWGSOP (Cruz-Jentoft et al., 2019). 
 
Muscle strength refers to the maximal amount of force a muscle can produce with a 
single effort. A decline in muscle strength has been shown to be associated with loss 
of lean muscle mass in older adults, but importantly occurs much more rapidly, 
meaning changes in muscle function can be detected earlier than change in mass 
(C. Cooper et al., 2013). Muscle power, which refers to the ability to exert a maximal 
force in as short a time as possible (power = strength x velocity), appears better still 
at predicting functional status as it declines earlier and faster than both muscle mass 
and strength (Beaudart et al., 2019). From an assessment perspective, isokinetic 
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dynamometry is seen as the gold standard from measuring muscle strength 
(Bohannon et al., 2012) and is also used to measure muscle power. Despite this, the 
use of these measures is often limited in the clinical setting due to cost and 
availability of expensive, cumbersome, specialist equipment (Beaudart et al., 2016). 
 
Global physical performance goes far beyond muscle function as it reflects not only 
cardiovascular adaptions to transport oxygen, but also the ability of skeletal muscle 
to utilise oxygen to meet the energy demands of physical activity (Tieland et al., 
2018). Cardiorespiratory fitness (CRF) is an intermediate variable between physical 
activity behaviours and health outcomes that reflect the capacity of numerous bodily 
organs, such as the heart, lungs and muscles, to support energy production during 
physical activity and exercise (Lang et al., 2018). CRF is known to decline with 
advancing age, with decreases in aerobic capacity, as measured by maximum 
oxygen uptake (VO2max), seen after the age of 30 and accelerating after the age of 
50 (Roman et al., 2016). Not only has CRF been shown to be an independent 
predictor of mortality, patients with lower CRF have higher mortality and morbidity as 
well as longer hospital stays when undergoing major surgery (Snowden et al., 2013). 
As with the changes seen in muscle mass and function, the age associated decline 
in VO2max is, in part, attributable to a reduction in physical activity seen in the elderly 
population (Roman et al., 2016). The decline is also the consequence of a drop in 
maximum cardiac output, as well as a reduction in skeletal muscles ability to extract 
oxygen (Roman et al., 2016; Weiss et al., 2006). In support of the notion that the 
decline in CRF is related to reduced physical activity, the speed of decline in aerobic 
capacity has been shown to be reduced if physical activity is maintained into older 
age, with a greater level of activity being associated with a greater VO2max (Roman et 
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al., 2016). Additionally, the age related decline seen in aerobic capacity has been 
shown to be improved even with relatively short exercise training programmes (J. 
Blackwell et al., 2017). 
 
Beyond the impact of reduced physical activity, the molecular and cellular 
disturbances responsible for the reduction in aerobic capacity seen in ageing are 
largely unknown. Although mitochondria have been implicated as a potential 
causative factor, the extent of mitochondrial decline and how this relates to poorer 
muscle quality and function, and subsequently global physical function, remain 
unresolved (Joseph et al., 2016). At a muscle fibre level, total mitochondrial content 
tends to be reduced in both type I and type II fibres (Roman et al., 2016) and cross 
sectional studies have shown age to be inversely related to vastus lateralis 
mitochondrial DNA and mRNA transcription (Short et al., 2005). This decline may 
result in lower muscle mitochondrial protein synthesis and thus changes in 
mitochondrial content and function. This would potentially explain why studies have 
shown that the reduced mitochondrial oxidative capacity seen after middle age is not 
fully reversed by endurance training (Santanasto et al., 2015). 
 
The aim of this study is to establish if the decline in global physical and muscle 
function is, in part, related to a decline in mitochondrial quality and function as 
measured using a high-resolution respirometer. In addition, this study will seek to 
explore the relationship between muscle function and global physical function across 




3.3 Experimental methods 
3.3.1 Recruitment and screening 
Participants were recruited by demographic targeted postal invitations and through 
presentations at local organisations. The study was approved by the University of 
Nottingham ethics committee (REF 407-1910) and complied with the Declaration of 
Helsinki (World Medical Association, 1964) 
 
Following a full explanation of the study by a member of the research team and 
granting of consent, potential participants underwent a screening session conducted 
by a qualified medical doctor. The session lasted less than an hour and consisted of 
a cardiorespiratory examination, resting blood pressure and heart rate 
measurements, a 12-lead electrocardiogram (ECG) and routine 
haematological/biochemistry blood profiles. All results were checked by a qualified 
medical doctor.  
3.3.2 Assessment of muscle function and physical performance 
3.3.2.1 Hand-grip strength 
Hand grip strength (HGS) is a good indicator of upper limb performance in everyday 
activity and has been shown to have prognostic value with respect to all-cause 
mortality, cardiovascular mortality and cardiovascular disease, along with playing an 




Maximum voluntary HGS contraction was assessed using an electric hand-grip 
dynamometer (Grip-D, takei, Japan). The participant was instructed to stand with 
their arm positioned at the side of the body, the elbow flexed at 90 degrees, before 
squeezing the dynamometer as hard as possible for 3 seconds (Leong et al., 2016). 
The assessment was repeated three times for both hands with at least 1 minute rest 
between each measurement. Both the maximum value and calculated mean were 
recorded.  
3.3.2.2 Short Physical Performance Battery Test (SPPBT) 
The SPPBT is a test calculated from three components:  
1. the ability to stand for 10 seconds with feet positioned in three ways (together 
side by side, semi-tandem and tandem),  
2. time to complete a 3m or 4m walk, and  
3. the time to rise to a standing position from a chair five times (Treacy & 
Hassett, 2018).  
The battery of tests focusses on lower extremity function since this has been shown 
to correlate with mobility, disability and patient outcomes including hospitalisation, 
institutionalisation and mortality (Beaudart et al., 2016). The SPPBT takes ~10 
minutes to complete with the test scored to a maximum of 12 points. Participants 
scoring  8 points have been described as having “poor” physical performance 
(Cruz-Jentoft et al., 2010). Although a useful tool in monitoring the physical function 
of frail or ‘at risk’ older adults, it is less effective in high functioning younger adults 




3.3.2.3 1 repetition maximal strength (1-RM) 
Due to the need for specialist equipment to perform isokinetic dynamometry, 
assessment of muscle strength is most often achieved using leg press or knee 
extension exercises. Maximal strength can be quantified through the one repetition 
maximum (1-RM) approach. 1-RM assessments determine the maximum single 
repetition that can be performed using free weights or traditional ‘dual phase’ 
(eccentric and concentric) resistance exercise training machine. In this study, 
unilateral knee extension was used. 
 
The test was performed follow a 5-minute warm up period on a static bike. 
Participants then sat on the weight machine, with adjustments being made according 
to height and comfort (i.e., pivot point of machine aligned with mid knee joint). 
Following a rest of one minute, the resistance was set at 50% of the anticipated 1-
RM weight and the participant was asked to complete 5 repetitions. If completed, the 
weight was increased to 70 – 75% of the anticipated 1-RM. Once the participant had 
rested for one minute, they were instructed to complete 5 repetitions at the new 
weight. If this was achieved and following another minute rest, a third set was 
performed at 85–90% of the predicted 1-RM and, as before, the participant should 
try to complete 5 repetitions. If the participant could only complete 1 repetition, this 
was deemed their 1-RM.  If the participant could complete between 2 and 4 
repetitions, a predicted 1-RM was calculated using the prediction coefficients shown 










Table 3 – 1-RM prediction coefficients (Brzycki, 1993) 
 
3.3.2.4 Cardiopulmonary exercise testing (CPET) 
CPET provides a global assessment of the integrative exercise responses allowing 
evaluation of both submaximal and peak exercise responses (Weisman et al., 2003). 
All tests took place in the Clinical Physiology Exercise Suite, University of 
Nottingham, Royal Derby Hospital and were supervised by members of the research 
team with at least Immediate Life Support (ILS) training. Prior to commencement of 
each CPET, the metabolic cart (ZAN 680, nSpire Health, USA) requires calibration. 
Firstly, room ambient conditions (room temperature (degree Celsius), humidity (%) 
and atmospheric pressure (mbar)) are recorded. The flow sensor is calibrated with a 
3 litres syringe attached to the cart. The inline gas analyser was calibrated against 
two precision gas mixtures (Weisman et al., 2003).  
 
Prior to setting up, the CPET protocol, including safety and termination criteria, was 
fully explained to the patient. Following this, a 12 lead ECG (CardioCollect12S, 
USA), non-invasive blood pressure (NIBP) monitoring and pulse oximeter were fitted 
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to the participant. Both cardiac tracing via ECG and oxygen saturations via pulse 
oximeter were recorded continuously through the test, with the NIBP recording every 
2 minutes. A silicone face mask was fitted to the participant using elasticated head 
gear (V2 mask, Hans Rudolph, USA). The flow sensor was then attached to the 
mask and the presence of any air leaks confirmed by occluding the end of the flow 
sensor whilst asking the participant to breathe out. Participants were then escorted 
to a cycle ergometer (Lode Corival, Lode, Netherlands) and the seat height and foot 
straps adjusted for comfort. 
 
Each CPET comprised of different stages as described in the literature (Weisman et 
al., 2003). The test started with a 2-minute warm up period of unloaded cycling to 
allow physiological equilibrium. The workload was then added in a ramp wise 
manner as per the Bruce Ramp protocol (Bruce, 1971). The ramp protocol was 
selected upon the basis of clinical opinion of an experienced CPET operator who will 
set incremental increases of between 5 – 30 Watts/minute with the aim of reaching 
peak oxygen consumption (VO2PEAK) in 8 – 12 minutes.  During the test, participants 
were encouraged to maintain a cadence of 50 – 60 revolutions per minute (RPM) 
and continue cycling until exhaustion. The CPET was ended when the participant 
indicated they had reached maximal effort, they were unable to maintain a cadence 
above 50 RPM or there was clinical concern as outlined by the American Thoracic 
Society Statement of Cardiopulmonary Exercise Testing ((Weisman et al., 2003). 
There was then a 5-minute recovery period of low wattage (10W) cycling in which 




In regard to this study, CPET analysis focused on the highest volume of oxygen 
utilised by the body, known as VO2max (Kinnear & Blakey, 2014). Absolute VO2max 
(L/min) achieved at CPET was determined as a 15 data point average, including the 
highest value attained, during the last 20 seconds of the test (Phillips et al., 2017). 
Tests were considered to have achieved VO2max if 3 or more of the following criteria 
were achieved (J. Blackwell et al., 2017): 
1) a plateau in the oxygen uptake curve (sustained flattening of VO2 curve despite 
rising VCO2). 
2) a respiratory exchange ratio (RER) of >1.15. 
3) HR over 85% age predicted maximum, and 
4) a rating of perceived exertion (RPE); modified Borg scale (Borg, 1982) 9 
immediately following the test 
3.3.3 Assessment of muscle architecture 
3.3.3.1 Ultrasonography 
Muscle thickness (MT), pennation angle (PA), fascicle length (FL) and cross-
sectional area (CSA) provide functional information regarding an individual’s lean 
muscle bulk and can be measured non-invasively using ultrasonography. Images 
were acquired using B-mode ultrasonography (Mylab, Esaote Biomedica, Italy) with 
a 100mm, 4 - 13MHz, linear array probe for MT, PA and FL measurements and a 
50mm, 4 – 13 MHz for CSA measurement. Participants were resting on an 
examination bed with knee in full extension as previously described (M. V. Franchi et 




To ensure the same portion of muscle was being measured in each participant, 
anatomical landmarks as described (Perkisas et al., 2018) were first identified by the 
ultrasound operator. For vastus lateralis (VL), the greater trochanter and proximal 
border of patella formed the longitudinal measurements, with the medial and lateral 
borders of the muscle (assessed using ultrasound) formed the sagittal 
measurements. The ultrasound transducer was then placed longitudinally and 
aligned to the fascicle plane to clearly visualise the fascicles. For CSA, the transduce 
probe was changed and the participant moved to the edge of the examination bed. 
Care was taken by the ultrasound operator to apply as little pressure when placing 
the probe on the skin as excessive compression has been shown to distort and 
flatten muscles by up to 50% (Dupont et al., 2001).  
 
Digital analysis of images was performed using ImageJ software (National Institutes 
for Health, USA). Muscle fascicle length was measured directly whenever possible, 
with linear extrapolation only being applied where the whole fascicle was not visible. 
The PA was measured at the fascicle intersection and deep tendon aponeurosis and 
MT was measured as the perpendicular distance between the superficial and deep 
aponeurosis. CSA was measured by tracing the outline of VL. An example of muscle 
architecture measurements can be seen in Figure 11. Three images from each 
ultrasound transducer were stored with each measurement repeated three times and 




Figure 11 - Ultrasound image of the VL muscle of a 29-year-old participant. Annotations show parameters 
relating to the assessment of muscle architecture. The two facial planes (superficial and deep) are shown in red 
lines with the muscle thickness being the distance between A and B (blue line). The yellow line from B to C 
represents muscle fascicle length using linear extrapolation, with the pennation angle shown in yellow and 
marked by the letter P. 
 
3.3.4 Assessment of body composition  
3.3.4.1 Dual-energy x-ray absorptiometry (DXA) 
Total mass, fat mass and lean tissue mass was assessed via dual-energy 
absorptiometry (DXA) scans on a GE Lunar Prodigy II scanner (GE Medical 
Systems, UK). DXA is non-invasive technique that generates low dose x-ray beams 
at two different energies, making use of the differential attenuation between the two 








DXA scans were performed by qualified research staff. Prior to the scan, participants 
remove all jewellery, ensure none of their clothing has any metal and not have a full 
bladder at the time of the scan. Participants are supine throughout the scan, with the 
duration of the scan varying between 6 – 11 minutes depending on their body mass. 
Along with whole body analysis, a customised region of interest (ROI) analysis was 
performed for the upper right leg (from greater trochanter to the midpoint of patella) 
(Figure 12) 
 




3.3.5 Assessment of mitochondrial activity 
3.3.5.1 VL muscle biopsy 
To assess mitochondrial activity, a small muscle biopsy was taken from the right VL 
of each participant. Percutaneous muscle biopsies are a well-established in both 
clinical and research practice, being deemed safe, effective and well tolerated 
technique (Baczynska et al., 2016). The procedure was explained, and consent 
confirmed prior to commencement. All biopsies were performed by qualified medical 
doctors with the samples being collected by a suitably trained member of the 
research team.  
 
The patient was supine with their right thigh exposed. Due to previous 
measurements performed for ultrasonography, the mid-point of VL was already 
marked. Following gowning and gloving, the biopsy site was cleaned with aseptic 
skin preparation (0.5% chlorhexidine solution) and sterile adhesive aperture drape 
placed over the site. The skin and overlying fascia were infiltrated with 5 – 10ml of 
local anaesthetic (1% lidocaine) with a 23G needle. Any spare local anaesthetic was 
kept in case any discomfort during the procedure was reported. A small 5 – 10mm 
skin incision was made using an 11 bladed scalpel. The scalpel blade was then 
advanced within the subcutaneous fat down to the fascia where a small incision 
made. A Weil-Blakesley conchotome was then used to obtain the muscle biopsy. 
The conchotome is an instrument designed like forceps but with a sharp biting tip 
(Baczynska et al., 2016). The conchotome was inserted through the skin incision 
with the tip opened and closed within the tissue and rotated through 90 – 180o to cut 




Once enough muscle had been collected, pressure was applied to the wound until 
haemostasis was confirmed. A single vertical mattress suture using 3/0 prolene 
(Ethicon) was placed across the incision, with the doctor performing the procedure 
ensuring the wound edges are appropriately approximated. Any further bleeding was 
controlled with direct pressure. For dressings, a semi-permeable dressing (Mepore 
Ultra) was placed over the wound, and a compression bandage (Pehaft) applied over 
it. Spare dressings and wound care advice was given to all participants, including 
advice to keep the wound dry and avoid vigorous physical activity for approximately 
72 hours.  
 
The amount of muscle obtained following repeated sampling can vary from 20mg to 
290mg (Baczynska et al., 2016). The muscle samples were cleaned, weighed, and 
placed in a buffer solution on ice for further analysis with Oroboros 2k high resolution 
respirometer. 
3.3.5.2 Oroboros 2k respiratory system 
The Oxygraph-2K (O2k, OROBOROS INSTRUMENTS, Austria) is a closed, two 
chamber HRR that allows mitochondrial energy metabolism to be tested 
comprehensively, in real time, by titrating various substrates, uncouplers, inhibitors, 
and other substances during the experiment (Long et al., 2019). Once the muscle 
biopsy was taken from the participant it was placed in ice cold buffer solution 
(BIOPS) and transferred to the clinical physiology laboratory, University of 
Nottingham, Royal Derby Hospital. The biopsy remained on ice and used within 4 




Prior to performing the HRR, the appropriate substrate-uncoupler-inhibitor-titration 
(SUIT) protocol was selected on Open DatLab software (SUIT-008_O2_pfi_DO14). 
There are multiple different SUIT protocols, each offering sensitive diagnostic tests 
for intact cells, permeabilised cells and permeabilised muscle cells (Pesta & Gnaiger, 
2012). We applied the SUIT 008 protocol in this study as it is an established and well 
validated protocol used in multiple other studies including those exploring the effects 
of immobilisation and ageing on muscle strength mitochondrial respiration (S. J. 
Edwards et al., 2020; Porter et al., 2015). The SUIT 008 protocol is specifically 
designed for use on permeabilised muscle fibres rather than isolated mitochondria 
and therefore provides a physiological relevant estimate of maximal mitochondrial 
respiration within that piece of muscle without the need for time consuming pre-
analysis mitochondrial isolation steps (S. J. Edwards et al., 2020). 
 
Both chambers of the Oxygraph-2K were rinsed with double distilled water (ddH2O) 
twice before 2.5ml mitochondrial respiration medium (Mir05) was added and 
chambers closed for calibration. The stirrers within the chambers were switched on 
and the system was left for 30 minutes to allow oxygen (O2) concentrations to 
stabilise.  
 
During this period, the muscle biopsy was prepared for testing. Firstly, a 12-well 
culture plates was labelled containing the following: 
• 1 x 1ml BIOPS 
• 1 x 2ml BIOPS + 20µl saponin stock 
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• 3 x 1ml Mir05 (labelled Mir05, chamber A, chamber B) 
The muscle biopsy was then transferred to a petri dish containing ice cold BIOPS 
and placed under a microscope. Using two 25G needles, any blood clots and 
connective tissue were cleared from the sample and the muscle was gently 
dissected into 2 – 5 mg bundles. The muscle bundles were then teased apart to 
expose individual fibres as shown in Figure 13. The individual muscle bundles were 
then transferred to the culture plate containing 1 ml BIOPS. The muscle biopsies 
were then transferred to the second well containing 2ml BIOPS + 20µl saponin stock 
and gently rocked on ice for 30 minutes. Following this, the muscle biopsies were 
transferred to the first well containing 1ml Mir05 and gently rocked on ice for a further 
10 minutes. The first muscle bundle was dabbed dry using Kim tech tissue and then 
weighed on the fine balance before transferred to into the well containing 1ml Mir05 
labelled chamber A. The weight of each bundle needs to be between 2 – 3 mg for 
processing in the Oxygraph-2K. The process was then repeated with the other 
muscle bundle and placed in chamber B.  
 
 
Figure 13 – An example of muscle fibres teased 
apart prior to transfer to culture plate. 
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Following the transfer of the muscle bundles into their respective chambers, sample 
information (experiment code, participant ID and biopsy number), along with the 
weight of the muscle bundles were entered into the software. Since the 
permeabilised muscle fibres are sensitive to oxygen supply, approximately 2ml of O2 
was injected to oxygenate each chamber. Once the trace is stable, there is a 
systematic addition of substrates, uncoupler and inhibitors to each chamber in order 
to assess mitochondrial respiration (Table 4). 
Step Substrate added Action 
1PM 15µl P/M solution (30µl pyruvate 
(P), 15µl malate (M)) 
Obtains complex I (CI)-linked LEAK 
respiration 
2D 20µl ADP Induces CI-linked OXOPHOS 
2c 5µl CytC Tests integrity of mitochondrial outer 
membrane 
3G 10µl Glutamate Allows observation of CI + II-linked OXPHOS 
4S 20µl Succinate Allows observation of CI + II-linked OXPHOS 
5U 1µl of 1mM FCCP additions until 
max flux achieved 
Maximum noncoupled respiration fuelled by 
complex II 
6Rot 2µl Rotenone Inhibits complex I and measures C II-linked 
OXOPHOS 
7Ama 1µl Antimycin A Inhibits C III 
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Table 4 - Summary of the substrates added to each chamber and the action they elicit on the mitochondria 
 
The point of adding each substrate was marked on the trace for subsequent analysis 
and the traces left to stabilise prior to the addition of the next substrate (see figure 
14). The O2 concentration was continuously monitored, with further O2 being injected 
into the chambers if the O2 concentration dropped below a certain level. In the event 
of this happening, the trace was left to stabilise before continuation of the run. Once 
completed, the contents of the chambers were aspirated and the lids and chambers 
were washed three times with ddH2O and increasing concentrations of ethanol (70%, 
100%). This ensured that all inhibitors are completely removed for next use.  
 
Figure 14 - An example trace using protocol SUIT-008_O2_pfi_DO14. The thick blue line represent O2 
concentration whilst the thick red line represent mitochondrial activity. Each substrate addition is identified by a 
thin, vertical blue line 
 
Digital analysis was carried out using the Open DatLab software. Between the points 
in which the various substrates were added, a mark was drawn manually over a 
section of time where the trace was most stable, as shown in Figure 15. The marks 
relate to each substrate addition (1PM, 2D,2c, 3G, 4S, 5U, 6Rot, 7Ama) and 
generated a range of data which was then exported for analysis. When assessing 
the mitochondrial response to the uncoupling agent, the maximum flux was marked 
to signify maximum respiration.  Where possible, the time sections used were similar 
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in both chambers.  The trace of both chambers was analysed, with data relating to 
specific flux (pmol/sec) and flux control ratio extracted and combined to form a 
median of both values.  
 
Figure 15 - An example of the analysis carried out on each of the traces. Between the addition of each substrate 
and prior to addition of a further substrate (thin, vertical blue lines), an area of the trace deemed most stable is 
marked for analysis (thin, vertical grey lines). 
3.3.6 Statistical analysis 
Descriptive data are presented as mean +/- standard error. Statistical significance 
was set at p < 0.05. Unpaired t tests were used for group analysis and Pearson’s 
correlation analysis was performed to establish the relationship between measures 
of global physical, muscle and cellular function and age. We report the correlation 
coefficient (r) with a corresponding p value for the model. All analysis was conducted 
on GraphPad Prism version 9.  
3.4 Results 
3.4.1 Subject baseline characteristics 
The baseline characteristics are shown in table 5. A total of 11 participants were 
recruited to the study and divided into young (18 – 40 years old) and old (>65 years 
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old) groups. There were no adverse events during the study and all subjects 
completed all aspects of the study day apart from the DXA scan. Due to a technical 
issue with the DXA scanner, 3 of the older participants were not able to have a scan. 
As such, due to low numbers available for comparison, DXA-derived analysis of 
body composition was not performed on the older participants. 
 
Sex Age a Height b Weight c BMI d 
Young participants 
Male 29 181 85.7 26.2 
Male 33 193 79.9 21.5 
Female 31 169.5 62.7 21.8 
Male 40 175 94.9 31 
Male 34 191 90.3 24.8 
Male 32 186.5 91.5 26.3 
 33.17 ( 3.76) 182.67 ( 9.23) 84.17 ( 11.73) 25.27 ( 3.30) 
Old participants 
Male 78 182 83 25.1 
Female 65 164 71 26.7 
Female 68 168 64.2 22.7 
Female 67 160 62 24.2 
Male 72 181.5 100.8 30.6 
 70 ( 5.15) 171.1 ( 10.13) 76.2 ( 16.0) 25.86 ( 3.02) 
P value <0.0001 0.788 0.365 0.773 
Table 5 - Summary of patient characteristics. Descriptive data represented as mean (SD) 




3.4.2 Assessment of global physical function 
For each of the three assessments of physical function, the older group recorded 
significantly lower measurements than the young (1-RM: 49.6kg vs. 25.62kg, p<0.03; 
HGS: 46.5kg vs. 31.6kg, p<0.03; VO2max: 44.72ml/kg*min vs. 24.56 ml/kg*min, 
p<0.01), indicating an age-associated decline in global physical function. The 
difference between means (+/- SEM) were -23.98kg +/- 8.190, p<0.05 for 1-RM, -
14.90kg +/- 5.906, p < 0.05 for HGS, and -20.16 +/- 5.541 ml/kg*min, p<0.01 for 
VO2max when comparing old against young (Figure 16 a-c, respectively). 
 
In relation to SPPB tests, all volunteers scored the maximum score of 12 and 
although it took the older participants longer to perform sit to stand, it was not 




Figure 16 - Measures of global physical fitness in young and old groups (a) 1-RM, b) HGS, c) VO2max). Graphs 
depict mean+/- SEM along with individual values. Analysis via unpaired students t-test. *=p<0.05, **=p<0.01. 
 
When assessing the relationship between different aspects of global physical 
function amongst all participants, with the exception of the young group HGS vs 
VO2max, there was a significant association between HGS and both 1-RM and VO2max 





Figure 17 - Correlation between different aspects of global functional fitness (a) HGS and 1-RM and (b) HGS and 
VO2max for young group (•) and old group (). Line represents simple linear regression. 
 
3.4.3 Assessment of skeletal muscle architecture 
There was no significant difference between the two age groups MT, FL and CSA. 
Regarding PA, the younger groups’ pennation angle was significantly larger than the 




Figure 18 - Measures of muscle architecture in young and old groups. (a) Muscle thickness, b) Fascicle length, c) 
Pennation angle, d) CSA). Graphs depict mean+/- SEM along with individual values. Analysis via unpaired 
students t-test. 
 
Since one of our aims was to assess the relationship between muscle mass and 
both global physical and cellular function, a measurement of muscle mass that was 
obtained for both groups was required. Unfortunately, due to DXA analysis not being 
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available for the older age group, the relationship between DXA derived lean leg 
mass and MT and CSA in the younger group was analysed in order to establish 
which measurement correlated best. Although there was a positive numerical 
correlation between DXA-derived lean leg mass and both CSA (Figure 19) and MT 
(Figure 20), neither reached significance. Despite this, because of the closer 
correlation, it was decided that CSA would be used as the measure for muscle mass 
that would be used in further analysis of results for both groups.  
 
Figure 19 - Correlation between CSA and leg lean mass as measured by DXA. Line represents simple linear 
regression. 
 
Figure 20 – Correlation between muscle thickness and leg lean mass as measured by DXA. Line represents 




3.4.4 Relationship between muscle architecture and global physical fitness 
A numerical positive correlation was seen between CSA, our measurement of 
muscle mass, and 1-RM, HGS and VO2max in both the young and old groups. 






Figure 21 - Correlation between measure of muscle mass (CSA) against measures of global physical fitness. (a) 
1-RM, b) HGS, c) VO2max). Lines represent simple linear regression for young (•) and old () groups. Pearson’s 




3.4.5 Assessment of changes in mitochondrial function in ageing 
There was no significant difference between young and old groups mitochondrial 
response to each substrate addition (Figure 21). The mitochondrial response of the 
two groups were then analysed according to their respiratory response relating 
specific stages of the mitochondrial respiratory chain (enzyme complex I (CI) and II 
(CII) activity, the maximum oxidative phosphorylation capacity (mO) and the 
maximum uncoupled capacity (mU)). Again, there was no significant difference 
between the two groups (Figure 22). 
 
 
Figure 22 –Mean mitochondrial response to substrate addition as measure by O2k two chambered respirometer. 
Graph depicts mean +/- SEM for both young and old groups substrate following pooling of individual values with x 































Figure 23 – Difference in mitochondrial respiratory function of a) Complex I activity, b) Complex II activity, c) 
Maximum oxidative phosphorylation capacity (mO) and d) Maximum uncoupled capacity (mU). Graph depicts 
mean +/- SEM for young and old groups. Analysis via 2-way ANOVA.  
 
3.4.6 Relationship between mitochondrial activity and global physical function 
There was no significant relationship between mitochondrial activity, measured as 
maximum oxidative phosphorylation capacity (mO) and maximum uncoupled 
capacity (mU), with measures of global fitness (1-RM, HGS and VO2max). 
Interestingly, although not significant, a negative relationship was found in all but 1-
RM in the young group (r=0.056) when mO was used as the measure of 
mitochondrial activity (Figure 23 a-c respectively), and in all groups when using mU 



















































































































Figure 24 – Correlation between mitochondrial maximum oxidative capacity (mO) and measures of global 





Figure 25 – Scatter plots demonstrating the relationship between mitochondrial maximum uncoupled capacity 
(mU) and measures of global physical fitness (a) 1-RM, b) HGS, c) VO2max). Lines represent simple linear 





As expected, this study showed a significant decline in global physical fitness with 
advancing age, even in independent community-dwelling older adults. A reduction in 
CRF with advancing age has been established by a significant evidence base ((Fleg 
et al., 2005; Proctor & Joyner, 1997)) and as such, this aspect of our findings is 
largely confirmatory. As previously mentioned, some of the decline in physical fitness 
is related to physical inactivity (Roman et al., 2016). Since the participants in our 
older group all reported recreationally active lives, we postulate that the age 
associated reduction in global physical fitness is not solely the result of disuse, rather 
the intrinsic effect of ageing. This suggestion agrees with previously published 
studies that implicate intrinsic mechanisms, such as structural and functional 
changes in skeletal muscle (Distefano & Goodpaster, 2018), cardiorespiratory 
changes including reduced cardiac output and muscle blood flow (Milanović et al., 
2013), and neuromuscular junction function loss (Joseph et al., 2016). 
 
Of potential clinical relevance, we saw an age-associated reduction in 1-RM of knee 
extension and HGS which, as alluded to above, is unlikely explained by reduced 
physical activity. Muscle strength has been shown to be a predictor of numerous 
health outcomes such as mortality, future disability, post-operative complications, 
and resource usage (Bohannon, 2008; R. Cooper et al., 2010) with both isometric 
measures having been shown to correlate with one another (Bohannon et al., 2012) 
as a reflection of overall limb muscle strength. Additionally, with the wealth of 
literature relating CRF to all-cause mortality (M. K. Edwards & Loprinzi, 2016; 
Snowden et al., 2013), it was promising that our study found positive correlation 
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between HGS with the assessment of both knee extensor strength and CRF. Based 
on these findings, HGS could be utilised as a cheap, easy method for predicting CRF 
in various clinical settings.  
 
It is well accepted that there is an age related reduction in muscle mass (C. Cooper 
et al., 2013). When assessing the effect of age on muscle architecture, we found a 
significant reduction in PA only, with MT and CSA numerically, but not significantly, 
lower in the older age group. The direction of change represented by these results is 
in agreement with much of the published literature, which shows a degree of 
alteration in these measures as we age (M. V. Narici et al., 2003; Ticinesi et al., 
2017). That we were unable to observe significant differences in MT and CSA is 
likely related to our small sample size since previous studies have shown age related 
differences in muscle architecture via ultrasound, with CSA of quadricep muscles 
being 25 – 33% different between young and older participants (M. V. Narici et al., 
2003).  
 
Along with MT, FL and PA represent the spatial arrangement of the muscle fibres 
within the muscle. PA represents muscle fibre arrangement in parallel, and has been 
shown to be linked with muscle strength by influencing mechanical efficacy of force 
transmission at the tendons and aponeurosis (Mpampoulis et al., 2021). FL 
represents muscle fibre arrangement in series and is more linked with power 
performance, with longer fascicles allowing faster contractions speeds. Both have 
been found to decrease with age (Marco V. Narici et al., 2021). Although not 
significant, the difference in FL observed between our young and older groups 
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suggested the older group had longer fascicles, a result that was not expected, nor 
can it be explained. Previous studies have shown that a reduction in both PA and FL 
could contribute to the reduced CSA seen in ageing (M. V. Narici et al., 2003). As 
such, this finding must be interpreted with caution, especially as no significant 
difference was found and a small sample size used. In addition, the role both PA and 
FL play in terms of clinical relevance has been questioned, with several studies 
suggesting they are not significantly related to functional muscle measurements and 
suggesting the use of MT or CSA instead (Kuyumcu et al., 2016; Strasser et al., 
2013).   
 
Muscle ultrasound measurements, such as MT and CSA, have been shown to have 
high concordance with both DXA and MRI-derived predicted values of muscle mass 
(Martino V. Franchi et al., 2020; Ticinesi et al., 2017). This suggests that 
ultrasonography could be a useful tool for the assessment of muscle mass, 
especially in the absence of research facilities. In agreement with existing research, 
our comparison of DXA values for lean muscle mass in the young group positively 
correlated with both MT and CSA values obtained using ultrasound. Although we 
failed to reach significance for either of these correlations, likely the result of the 
small sample size, the findings need to be further investigated in the future including 
data from older adults. Furthermore, by using an ultrasound-based measure of CSA, 
we were able to show a positive correlation between muscle mass and HGS, 1-RM 
and VO2max in both the young and older groups. Again although these correlations 
failed to reach statistical significance, the findings in agreement with other studies 
that have shown CSA to be associated with measures of global physical function (C. 




Contrary to the findings relating to the assessments of physical function, we did not 
find any significant difference in mitochondrial respiratory capacity in response to 
substrate addition between the age groups. This differs from prior research, in which 
a substantial fall in several pathways of ATP synthesis, including anaerobic 
glycolysis and oxidative phosphorylation, have been shown to be impaired in ageing 
skeletal muscle (Tieland et al., 2018; Trounce et al., 1989). Furthermore, our results 
also found no link between a mitochondrial respiration capacity and measures of 
global physical function, with our results showing that participants with the highest 
measures of global physical fitness had some of the lowest mitochondrial respiration 
responses. These conclusions must be taken with caution due to our low sample 
size and lack of statistically significant results. The results do however highlight 
challenges related to researching the true impact of ageing on mitochondrial 
dysfunction, with some previous studies supporting a decrease in mitochondrial 
capacity (Porter et al., 2015; Tonkonogi et al., 2003; Trounce et al., 1989), whilst 
others have failed to find such association (Gouspillou et al., 2014; Hütter et al., 
2007; Larsen et al., 2012). 
 
That we report no relationship between mitochondrial respiratory capacity and global 
physical fitness or age may be, in part, related to our selection of physically active, 
healthy older participants. Recent studies have suggested that maintaining physical 
activity into old age mitigates the negative effects usually seen with ageing, with 
physically active young and old groups having similar protein markers of 
mitochondrial content and respiration (S. Choi et al., 2016; St-Jean-Pelletier et al., 
2017). Despite this, VO2peak has been shown to be lower in older groups, even with 
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similar mitochondrial energetics (Beere et al., 1999), suggesting the effect age has 
on other physiological determinants, such as cardiac output and muscle perfusion, 
cannot be fully reversed by physical activity. 
3.5.1 Limitations 
There are several limitations to this study which should be acknowledged, the main 
being the low sample size resulting in statistically underpowered results. Despite 
significance being reached in demonstrating age-related declines in global physical 
fitness and a relationship between different measures of global physical function, we 
failed to show a significant association between global physical fitness and muscle 
mitochondrial function, or any age-associated difference in mitochondrial function. 
For any firm conclusions to be made, a larger sample size is needed.  
 
Although self-selection bias can occur in all age-groups when individuals volunteer 
for research, health problems and functional limitations increase with age (Golomb et 
al., 2012). As such, older age research participants are less likely to represent their 
age group than in younger cohorts. This is particularly relevant in a study involving 
physical function tests as it may deter more sedentary individuals. To mitigate this 
limitation, we would again need to increase the number of participants and 
purposefully seek older adults who are representative of their age-group (i.e., in 
respect to comorbidities, polypharmacy and functional status). 
 
Finally, in the OROBOROS method used, we added substrate quantities more than 
those seen in vivo conditions. Additionally, the use of isolated mitochondria has been 
shown to exaggerate the observed deficit in mitochondrial function (Distefano et al., 
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2018). As such, these results do not necessarily reflect what occurs in the human 
body 
3.6 Conclusion 
The study shows that there is clearly a decline in global physical function associated 
with advancing age that is unlikely linked to physical inactivity. Unfortunately, we 
failed to show the anticipated links between the physical function and both muscle 
and mitochondrial function, although this is likely due to a small sample size. Further 
work is required, using a greater number of participants of varying physical fitness 
status, to gain a greater understanding of the impact not only age, but also level of 








With the worldwide population living longer, the importance of preserving health and 
quality of life with advancing age is vital. It is well established that there is a 
progressive change in muscle mass, metabolism and functional capacity in ageing, 
which is associated with loss of independence and increased total mortality (Shur et 
al., 2021). Despite this, the complex mechanisms underpinning sarcopenia and the 
associated detrimental impacts are not yet fully understood. With many of the 
physiological features seen in ageing also being associated with inactivity, increasing 
the physical activity of older individuals is now seen as a crucial preventative target in 
maintaining muscle mass and function, and subsequent overall health. One area that 
remains poorly understood is the role mitochondrial dysfunction plays in skeletal 
muscle ageing – the focus of this thesis.  
 
Our aim for the healthy volunteer study presented in Chapter 3 of this thesis was to 
build on existing evidence demonstrating the differences in global physical and 
muscle functions with ageing, as well as attempt to gain more knowledge regarding 
possible changes in mitochondrial respiration with advancing age. Our results agreed 
with other studies reporting a significant difference between global physical function 
measures between young and older participants. We also showed a numerical, but 
not statistically significant, difference in measurements of muscle architecture (with 
statistical analysis likely limited by a small sample size), and a positive correlation 
between muscle CSA and measures of global fitness. These correlations suggest a 
clear relationship between skeletal muscle mass and function, however given the fact 
muscle strength is lost much more rapidly than muscle mass (Mitchell et al., 2012), it 




The concept of age-related mitochondrial dysfunction remains under considerable 
debate, and as such so does its implication in age-associated reduction in physical 
function. Our healthy volunteer study, although underpowered for this analysis, 
appeared to show what recent studies have also indicated - that physical activity, 
rather than chronological age, influences mitochondrial function (Distefano et al., 
2018). Since our older participants all led active lifestyles, our results are in line with 
two recent reports showing that physically active young and old groups had similar 
mitochondrial respiration (Gouspillou et al., 2014; St-Jean-Pelletier et al., 2017). This 
contrasts other work by both Trounce et al and Porter et al., which showed significant 
negative correlation between mitochondrial respiratory capacity and age (Porter et 
al., 2015; Trounce et al., 1989). These differing opinions highlight the complexity 
when trying to draw firm conclusions regarding the true impact ageing has on 
mitochondrial function, mainly due to the multiple covariates (including physical 
activity, cardiovascular fitness and adiposity) that also affect mitochondrial function 
(Distefano et al., 2018). A future study with a greater number of participants, with 
varying levels of habitual physical activity, would be needed to gain a greater insight 
into possible changes seen with age and confirm the seemingly greater influence of 
physical activity status.  
 
Moving on to consider the impact of age-associated disease on skeletal muscle mass 
and function, our systematic review and meta-analysis performed in Chapter 2 of the 
thesis showed that pre-existing sarcopenia in patients with LARC resulted in a 
significantly shortened OS, as well as an association with shorter DFS. Since the 
underlying aetiology of sarcopenia is multifactorial and complex, especially on a 
background of disease, there remains very few therapeutic options. This has led to 
an increasing focus on preventing muscle loss in the older population to improve 
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clinical outcomes. Although it has been shown that physical exercise training prior to 
major surgery can improve cardiorespiratory fitness (Berkel et al., 2018; Boereboom 
et al., 2016), there is less robust evidence demonstrating that prehabilitation increase 
muscle mass or improves mitochondrial function. Additionally, very little is known 
about the impact of nCRT has on skeletal muscle mitochondria.  
 
The findings presented in this thesis illustrate a large scope for potential future 
research that can be applied in the clinical setting. Our research group has previously 
shown that patients with colorectal cancer demonstrate reduced muscle protein 
synthesis (MPS) and trend towards increased muscle protein breakdown (MPB), both 
of which were reversed following surgical resection (Williams et al., 2012). This, in 
combination with studies showing a mixed response to preoperative exercise 
programs in individuals with various cancers (J. E. M. Blackwell et al., 2020; 
Boereboom et al., 2019), suggests that the pathological and systemic effects of 
various forms of cancers effect global physical fitness and muscle function differently. 
What has so far been poorly investigated is the impact of cancer on mitochondrial 
function, quantity and its relationship with overall skeletal muscle mass and global 
physical fitness. In animal studies, the presence of cancer has been shown to reduce 
mitochondrial content in skeletal muscle. Further to this, animals treated with 
chemotherapy agents have shown long term impairment in mitochondrial respiration 
and increase ROS within skeletal muscle (Gouspillou et al., 2015). The interest in this 
field is growing in human studies, with study groups in both Sweden and Taiwan 
registering clinical trials investigating the effects of different forms of exercise 
programs have on skeletal muscle mitochondrial function in patients receiving neo-




No study has yet investigated the mitochondrial function of patients with various 
cancer types, who all undergo chemotherapy prior to surgical resection. A study of 
this nature would build on our understanding of why certain cancer types appear to 
respond better to exercise programs than others and determine the impact of cancer 
and its treatment has on mitochondrial function. In addition, by following these 
patients throughout their treatment pathway, the results gained could provide 
enhanced understanding at to what other changes occur to skeletal muscle, both 
structurally and on a cellular level. A full study design for this proposed future work in 
the form of a research ethics application can be found in Appendix B 
 
In conclusion, this thesis builds on existing knowledge relating to the impact of age 
has on skeletal muscle mass and function, as well as providing preliminary data on 
the impact ageing has on mitochondrial function using a contemporary analysis 
method that has not been used by our research group previously. Finally, based on 
the findings in systematic review and meta-analysis, along with the healthy volunteer 
study outlined in the chapters of this thesis, a future study design that could help 
answer questions relating to the relationship of mitochondrial dysfunction in age and 
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5.1 Appendix A 
Search Strategy HDAS Medline 
 
NEOPLASMS/ OR exp NEOPLASMS/ OR exp NEOPLASMS/su OR exp "ANUS 
NEOPLASMS"/ OR exp "BILIARY TRACT NEOPLASMS"/ OR exp "BILE DUCT 
NEOPLASMS"/ OR exp "CECAL NEOPLASMS"/ OR exp "COLONIC 
NEOPLASMS"/ OR exp "COLORECTAL NEOPLASMS"/ OR exp "DIGESTIVE 
SYSTEM NEOPLASMS"/ OR exp "GASTROINTESTINAL NEOPLASMS"/ OR exp 
"INTESTINAL NEOPLASMS"/ OR exp "LIVER NEOPLASMS"/ OR exp 
"PANCREATIC NEOPLASMS"/ OR exp "PELVIC NEOPLASMS"/ OR exp 
"PROSTATIC NEOPLASMS"/ OR exp "RECTAL NEOPLASMS"/ OR "SIGMOID 
NEOPLASMS"/ OR exp "STOMACH NEOPLASMS"/ OR exp "UROGENITAL 
NEOPLASMS"/ OR exp "UROLOGIC NEOPLASMS"/ OR exp "NEOPLASM 
METASTASIS"/ OR exp "ABDOMINAL NEOPLASMS"/ OR (abdo* OR cancer OR 




"NEOADJUVANT THERAPY"/ OR exp "COMBINED MODALITY THERAPY"/ OR 
(neoadjuvant ADJ2 therapy).ti,ab OR (chemorad*).ti,ab OR ("neodjuvant 




exp COLECTOMY/ OR exp PROCTECTOMY/ OR exp "SURGICAL PROCEDURES, 
OPERATIVE"/ OR (excis* OR resect* OR surg*).ti,ab 
 
AND 
((musc*).ti,ab AND (function* OR strength OR mass OR loss OR wast* OR power 
OR deplet*).ti,ab) OR ((skeletal).ti,ab AND (function* OR strength OR mass OR loss 
OR wast* OR power OR deplet*).ti,ab) OR (sarcopenia).ti,ab OR SARCOPENIA/ OR 
exp "MUSCULAR ATROPHY"/ OR exp "MUSCLE CONTRACTION"/ OR exp 
"MUSCLE RELAXATION"/ OR exp "MUSCLE STRENGTH"/ OR exp 
"MUSCULOSKELETAL AND NEURAL PHYSIOLOGICAL PHENOMENA"/ 
 
AND 
(prognosis OR surviv*).ti,ab OR exp "TREATMENT OUTCOME"/ OR exp 
PROGNOSIS/ OR "DISEASE-FREE SURVIVAL"/ OR "PROGRESSION-FREE 




exp "CASE-CONTROL STUDIES"/ OR (observational study).ti,ab,pt OR (case-
control stud*).ti,ab,pt OR (randomized controlled trial OR randomised controlled 
trial).ti,ab,pt OR ("retrospective stud*").ti,ab,pt OR ("systematic review").ti,ab,pt OR 
("review").ti,ab,pt OR ("meta analysis").ti,ab,pt OR ("cohort stud*").ti,ab,pt OR 
"OBSERVATIONAL STUDY"/ OR exp "RANDOMIZED CONTROLLED TRIAL"/ OR 
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"SYSTEMATIC REVIEW"/ OR exp REVIEW/ OR "META-ANALYSIS"/ OR 




# Database Search term Results 
1 Medline NEOPLASMS/ 428375 
2 Medline exp NEOPLASMS/ 3380357 
3 Medline exp NEOPLASMS/su 539586 
4 Medline exp "ANUS NEOPLASMS"/ 6413 
5 Medline exp "BILIARY TRACT 
NEOPLASMS"/ OR exp "BILE 
DUCT NEOPLASMS"/ 
28742 
6 Medline exp "CECAL NEOPLASMS"/ 5610 
7 Medline exp "COLONIC NEOPLASMS"/ 75179 
8 Medline exp "COLORECTAL 
NEOPLASMS"/ 
203568 
9 Medline exp "DIGESTIVE SYSTEM 
NEOPLASMS"/ 
626437 
10 Medline exp "GASTROINTESTINAL 
NEOPLASMS"/ 
382767 
11 Medline exp "INTESTINAL 
NEOPLASMS"/ 
229773 
12 Medline exp "LIVER NEOPLASMS"/ 166987 
13 Medline exp "PANCREATIC 
NEOPLASMS"/ 
76847 
14 Medline exp "PELVIC NEOPLASMS"/ 7099 
15 Medline exp "PROSTATIC 
NEOPLASMS"/ 
129563 
16 Medline exp "RECTAL NEOPLASMS"/ 47680 
17 Medline "SIGMOID NEOPLASMS"/ 4607 
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19 Medline exp "UROGENITAL 
NEOPLASMS"/ 
515660 
20 Medline exp "UROLOGIC 
NEOPLASMS"/ 
135583 
21 Medline exp "NEOPLASM 
METASTASIS"/ 
205276 
22 Medline exp "ABDOMINAL 
NEOPLASMS"/ 
34008 
23 Medline (abdo* OR cancer OR metas* 
OR malign*).ti,ab 
2557432 
24 Medline (1 OR 2 OR 3 OR 4 OR 5 OR 6 
OR 7 OR 8 OR 9 OR 10 OR 11 
OR 12 OR 13 OR 14 OR 15 OR 
16 OR 17 OR 18 OR 19 OR 20 
OR 21 OR 22 OR 23) 
4266580 
25 Medline "NEOADJUVANT THERAPY"/ 
OR exp "COMBINED 
MODALITY THERAPY"/ 
266022 
26 Medline (neoadjuvant ADJ2 
therapy).ti,ab 
8897 
27 Medline (chemorad*).ti,ab 84 
28 Medline ("neodjuvant 
chemotherapy").ti,ab 
9 
29 Medline (neodjuvant 
chemotherapy).ti,ab 
18 
30 Medline (25 OR 26 OR 27 OR 28 OR 
29) 
269792 
31 Medline exp COLECTOMY/ 20948 
32 Medline exp PROCTECTOMY/ 3978 
33 Medline exp "SURGICAL 
PROCEDURES, OPERATIVE"/ 
3197525 
34 Medline (excis* OR resect* OR 
surg*).ti,ab 
2154938 
35 Medline (31 OR 32 OR 33 OR 34) 4306359 
36 Medline (musc*).ti,ab 788042 
37 Medline (function* OR strength OR 
mass OR loss OR wast* OR 
power OR deplet*).ti,ab 
5744176 
38 Medline (skeletal).ti,ab 200614 
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39 Medline (36 AND 37) 278716 
40 Medline (37 AND 38) 73804 
41 Medline (sarcopenia).ti,ab 8148 
42 Medline SARCOPENIA/ 4684 
43 Medline exp "MUSCULAR ATROPHY"/ 15635 
44 Medline exp "MUSCLE 
CONTRACTION"/ 
200184 
45 Medline exp "MUSCLE RELAXATION"/ 29854 
46 Medline exp "MUSCLE STRENGTH"/ 34575 





48 Medline (39 OR 40 OR 41 OR 42 OR 43 
OR 44 OR 45 OR 46 OR 47) 
2603263 
49 Medline (prognosis OR surviv*).ti,ab 1419450 
50 Medline exp "TREATMENT 
OUTCOME"/ OR exp 
PROGNOSIS/ 
1693647 
51 Medline "DISEASE-FREE SURVIVAL"/ 
OR "PROGRESSION-FREE 
SURVIVAL"/ OR "REMISSION 
INDUCTION"/ 
116419 
52 Medline exp "CASE-CONTROL 
STUDIES"/ 
1115615 
53 Medline (observational study).ti,ab,pt 191316 
54 Medline (case-control stud*).ti,ab,pt 124608 




56 Medline ("retrospective stud*").ti,ab,pt 164298 
57 Medline ("systematic review").ti,ab,pt 193115 
58 Medline ("review").ti,ab,pt 3343679 
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59 Medline ("meta analysis").ti,ab,pt 186839 
60 Medline ("cohort stud*").ti,ab,pt 218707 
61 Medline "OBSERVATIONAL STUDY"/ 0 
62 Medline (49 OR 50 OR 51) 2699616 
63 Medline exp "RANDOMIZED 
CONTROLLED TRIAL"/ 
0 
64 Medline "SYSTEMATIC REVIEW"/ 0 
65 Medline exp REVIEW/ 0 
66 Medline exp REVIEW/ 0 
67 Medline "META-ANALYSIS"/ 0 
68 Medline "RETROSPECTIVE STUDIES"/ 
OR "COHORT STUDIES"/ 
1057894 
69 Medline (52 OR 53 OR 54 OR 55 OR 56 
OR 57 OR 58 OR 59 OR 60 OR 
61 OR 63 OR 64 OR 65 OR 66 
OR 67 OR 68) 
5358100 
70 Medline (24 AND 30 AND 35 AND 48 
AND 62) 
1469 
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Search Strategy HDAS Embase 
 
exp NEOPLASM/ OR exp "ANUS TUMOR"/ OR exp "BILIARY TRACT TUMOR"/ OR 
exp "CECUM TUMOR"/ OR exp "COLON TUMOR"/ OR exp "COLORECTAL 
TUMOR"/ OR exp "DIGESTIVE SYSTEM TUMOR"/ OR exp "GASTROINTESTINAL 
TUMOR"/ OR exp "INTESTINE TUMOR"/ OR exp "LIVER TUMOR"/ OR exp 
"PANCREAS TUMOR"/ OR exp "PELVIS TUMOR"/ OR exp "PROSTATE TUMOR"/ 
OR exp "RECTUM TUMOR"/ OR exp "STOMACH TUMOR"/ OR exp "UROGENITAL 
TRACT TUMOR"/ OR exp "URINARY TRACT TUMOR"/ OR exp "LARGE 
INTESTINE TUMOR"/ exp "INTESTINE TUMOR"/ OR exp METASTASIS/ OR exp 




exp "NEOADJUVANT THERAPY"/ OR "MULTIMODALITY CANCER THERAPY"/ 
OR (neoadjuvant ADJ2 therapy).ti,ab OR (chemorad*).ti,ab OR ("neodjuvant 
chemotherapy").ti,ab OR (neodjuvant chemotherapy).ti,ab 
 
AND 
exp "COLON RESECTION"/ OR exp "RECTUM RESECTION"/ OR exp SURGERY/ 
OR (excis* OR resect* OR surg*).ti,ab 
 
AND 
((musc*).ti,ab  AND (function* OR strength OR mass OR loss OR wast* OR power 
OR deplet*).ti,ab) OR ((skeletal).ti,ab AND (function* OR strength OR mass OR loss 
OR wast* OR power OR deplet*).ti,ab) OR (sarcopenia).ti,ab OR SARCOPENIA/ OR 
exp "MUSCULAR ATROPHY"/ OR exp "MUSCLE CONTRACTION"/ OR exp 
"MUSCLE RELAXATION"/ OR exp "MUSCLE STRENGTH"/ 
 
AND 
(prognosis OR surviv*).ti,ab OR exp "TREATMENT OUTCOME"/ OR exp 
PROGNOSIS/ OR "DISEASE COURSE"/ OR exp SURVIVAL/ OR exp "DISEASE 
FREE SURVIVAL"/ OR exp REMISSION/ 
 
AND 
exp "CASE CONTROL STUDY"/ OR (observational study).ti,ab,pt  OR (case-control 
stud*).ti,ab,pt  OR  (randomized controlled trial OR randomised controlled 
trial).ti,ab,pt OR ("retrospective stud*").ti,ab,pt OR ("systematic review").ti,ab,pt OR 
("review").ti,ab,pt OR ("meta analysis").ti,ab,pt OR ("cohort stud*").ti,ab,pt OR exp 
"OBSERVATIONAL STUDY"/ OR exp "RANDOMIZED CONTROLLED TRIAL"/ OR 
"SYSTEMATIC REVIEW"/ OR exp REVIEW/ OR exp "META ANALYSIS"/ OR 




# Database Search term Results 
1 EMBASE exp NEOPLASM/ 4574377 
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2 EMBASE exp "ANUS TUMOR"/ 9927 
3 EMBASE exp "BILIARY TRACT 
TUMOR"/ 
50699 
4 EMBASE exp "CECUM TUMOR"/ 2276 
5 EMBASE exp "COLON TUMOR"/ 331718 
6 EMBASE exp "COLORECTAL TUMOR"/ 30069 
7 EMBASE exp "DIGESTIVE SYSTEM 
TUMOR"/ 
1023354 
8 EMBASE exp "GASTROINTESTINAL 
TUMOR"/ 
27209 
9 EMBASE exp "INTESTINE TUMOR"/ 414447 
10 EMBASE exp "LIVER TUMOR"/ 287123 
11 EMBASE exp "PANCREAS TUMOR"/ 149983 
12 EMBASE exp "PELVIS TUMOR"/ 7899 
13 EMBASE exp "PROSTATE TUMOR"/ 249156 
14 EMBASE exp "RECTUM TUMOR"/ 264815 
15 EMBASE exp "STOMACH TUMOR"/ 152114 
16 EMBASE exp "UROGENITAL TRACT 
TUMOR"/ 
819348 
17 EMBASE exp "URINARY TRACT 
TUMOR"/ 
230790 
18 EMBASE exp "LARGE INTESTINE 
TUMOR"/ OR exp "INTESTINE 
TUMOR"/ 
414447 
19 EMBASE exp METASTASIS/ 647645 
20 EMBASE exp "ABDOMINAL TUMOR"/ 43903 
21 EMBASE (abdo* OR cancer OR metas* 
OR malign*).ti,ab 
3652022 
22 EMBASE (1 OR 2 OR 3 OR 4 OR 5 OR 6 
OR 7 OR 8 OR 9 OR 10 OR 11 
OR 12 OR 13 OR 14 OR 15 OR 
5558679 
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16 OR 17 OR 18 OR 19 OR 20 
OR 21) 
23 EMBASE exp "NEOADJUVANT 
THERAPY"/ 
25938 
24 EMBASE "MULTIMODALITY CANCER 
THERAPY"/ 
70822 
25 EMBASE (neoadjuvant ADJ2 
therapy).ti,ab 
15554 
26 EMBASE (chemorad*).ti,ab 50575 
27 EMBASE ("neodjuvant 
chemotherapy").ti,ab 
32 
28 EMBASE (neodjuvant 
chemotherapy).ti,ab 
32 
29 EMBASE (23 OR 24 OR 25 OR 26 OR 27 
OR 28) 
146465 
30 EMBASE exp "COLON RESECTION"/ 44510 
31 EMBASE exp "RECTUM RESECTION"/ 18722 
32 EMBASE exp SURGERY/ 4928835 
33 EMBASE (excis* OR resect* OR 
surg*).ti,ab 
2944649 
34 EMBASE (30 OR 31 OR 32 OR 33) 5746455 
35 EMBASE (musc*).ti,ab 1084502 
36 EMBASE (function* OR strength OR 
mass OR loss OR wast* OR 
power OR deplet*).ti,ab 
7352294 
37 EMBASE (35 AND 36) 411819 
38 EMBASE (skeletal).ti,ab 248873 
39 EMBASE (36 AND 38) 99770 
40 EMBASE (sarcopenia).ti,ab 13372 
41 EMBASE SARCOPENIA/ OR exp 
"MUSCLE ATROPHY"/ 
43886 
42 EMBASE exp "MUSCLE 
CONTRACTION"/ 
120152 
43 EMBASE exp "MUSCLE RELAXATION"/ 23897 
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44 EMBASE exp "MUSCLE STRENGTH"/ 65572 
45 EMBASE (37 OR 39 OR 40 OR 41 OR 42 
OR 43 OR 44) 
585737 
46 EMBASE (prognosis OR surviv*).ti,ab 2086043 
47 EMBASE exp "TREATMENT 
OUTCOME"/ 
1725481 
48 EMBASE exp PROGNOSIS/ 748026 
49 EMBASE "DISEASE COURSE"/ 460533 
50 EMBASE exp "DISEASE FREE 
SURVIVAL"/ 
87528 
51 EMBASE exp SURVIVAL/ 1156866 
52 EMBASE exp REMISSION/ 205418 
53 EMBASE (46 OR 47 OR 48 OR 49 OR 50 
OR 51 OR 52) 
4360504 
54 EMBASE exp "CASE CONTROL 
STUDY"/ 
183174 
55 EMBASE (observational study).ti,ab,pt 138068 
56 EMBASE (case-control stud*).ti,ab,pt 139244 




58 EMBASE ("retrospective stud*").ti,ab,pt 263338 
59 EMBASE ("systematic review").ti,ab,pt 212667 
60 EMBASE ("review").ti,ab,pt 3785725 
61 EMBASE ("meta analysis").ti,ab,pt 209737 
62 EMBASE ("cohort stud*").ti,ab,pt 321782 
63 EMBASE exp "OBSERVATIONAL 
STUDY"/ 
215825 
64 EMBASE exp "RANDOMIZED 
CONTROLLED TRIAL"/ 
635724 
65 EMBASE "SYSTEMATIC REVIEW"/ 273959 
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66 EMBASE exp REVIEW/ 2702744 
67 EMBASE exp "META ANALYSIS"/ 203612 
68 EMBASE "RETROSPECTIVE STUDY"/ 1001216 
69 EMBASE "COHORT ANALYSIS"/ 644864 
70 EMBASE (54 OR 55 OR 56 OR 57 OR 58 
OR 59 OR 60 OR 61 OR 62 OR 
63 OR 64 OR 65 OR 66 OR 67 
OR 68 OR 69) 
6225288 
71 EMBASE (22 AND 29 AND 34 AND 45 
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5.2 Appendix B 
 
The impact of cancer, chemotherapy, and 






Short title:  Impact of cancer, chemotherapy, and exercise on 
mitochondria. 
 
Acronym:    ICCE-Mito 
 
Trial Registration:  NCT04558398 
 
ISRCTN:    if appropriate 
 
IRAS Project ID: 275264 
 
Trial Sponsor:   University of Nottingham 
 
Sponsor reference: 20019 
 
Funding Source: Research funds of Mr Jon Lund  
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TRIAL / STUDY PERSONNEL AND CONTACT DETAILS 
Sponsor:  University of Nottingham 
Contact name: Ms Angela Shone 
   Head of Research Governance 
   Research and Graduate Services 
   King’s Meadow Campus 
   Lenton Lane 
   Nottingham 
   NG7 2NR 
Email:   sponsor@nottingham.ac.uk  
 
Chief investigator:           
Mr Jon Lund DM, FRCS 
Clinical Associate Professor and Consultant colorectal surgeon 
Phone: 01332 724641   
Email: jon.lund@nottingham.ac.uk 
 
Co-investigators:   
Dr Bethan Phillips, BSc (Hons), PhD, Research Fellow, Division of Graduate Entry 
Medicine and Health, School of Medicine, University of Nottingham.  
Email: beth.phillips@nottingham.ac.uk 
 
Mr Jacob Hatt, Clinical Research Fellow, MBChB, BSc (Hons), MRCSEd. (PhD 
Student) Division of Graduate Entry Medicine and Health, School of Medicine, 
University of Nottingham 
Email: jacob.hatt@nhs.net / mzxjh2@nottingham.ac.uk 
 
Mr Thomas Smart, Clinical Research Fellow, MBBS, BSc (Hons), MRCSEd. (PhD 
Student) Division of Graduate Entry Medicine and Health, School of Medicine, 
University of Nottingham 
Email: thomas.smart2@nhs.net / mzxts@nottingham.ac.uk 
   
Trial / Study Statistician: 
Dr Brett Doleman. Clinical Fellow, Royal Derby Hospital, Derby. 
Email: dr.doleman@gmail.com 
 
Trial / Study Coordinating Centre:  
University of Nottingham, Royal Derby Hospital, School of Medicine, Royal Derby 
Hospital, 
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SYNOPSIS 
 
Title The impact of cancer, chemotherapy, and resistance exercise training 
(RET) on mitochondrial activity. 
Acronym ICCE-Mito 
Short title Cancer and mitochondrial activity 
Chief Investigator Mr Jon Lund 
Objectives Primary Objectives:   
To assess the impact of cancer and neoadjuvant chemotherapy have on 
mitochondrial activity. 
 
To assess the impact of cancer and neoadjuvant chemotherapy on body 
composition and muscle function. 
 
To investigate if preoperative home RET programme can improve 
mitochondrial activity, body composition and muscle function in patients 
awaiting surgery for intra-abdominal cancer.  
 
Secondary Objectives:  
To investigate myokine levels in different types of cancer and the impact 
neo adjuvant treatment has on these markers. 
 
To establish if physiological responses to home RET differ between 
cancer types.  
 
Trial Configuration Single centre pilot study.  
Setting Royal Derby Hospital, Secondary Referral Centre (NHS) and 
University of Nottingham.  
Sample size estimate A formal sample size calculation for this study is not possible due to the 
absence of comparable data for our primary endpoint. As such this study 
will be conducted as a single centre pilot study. Despite this, sample 
sizes like that proposed herein have been used to demonstrate changes 
in mitochondrial activity in response to alternative interventions and we 
have previously reported changes in body composition and function as a 
result of RET in samples groups of this size.  
Number of participants 64 participants will be required to complete the study in the following 
groups: 
 
n = 8 breast cancer patients 
n = 16 oesophageal cancer patients (8 will require neoadjuvant 
chemotherapy) 
n = 16 prostate cancer patients (8 will undergo home RET) 
n = 24 colorectal cancer patients (8 will undergo home RET, 8 will 
require neoadjuvant chemotherapy). 
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Based on past experience of recruiting cancer patients for exercise 
training studies, up to 68 participants will be recruited to allow for an 
anticipated 20% drop out rate.  
Eligibility criteria Adult patients 50 years or over diagnosed with oesophageal, breast, 
prostate or colorectal cancer that are deemed eligible to undergo 
resectional surgery and are physically capable of performing RET 
(prostate and colorectal cancer patients only). 
Description of 
interventions 
An intervention will only be delivered to the RET arm in each of prostate 
and colorectal cancer patients’ groups. All other participants will have 
physiological investigations at different times within their normal 
treatment pathway.  
 
After they have provided informed consent and attended an initial 
screening session to ensure eligibility for the study. All participants will 
undergo a study session on the morning of their planned surgery day 
consisting of: 
 
A muscle (m. vastus lateralis (VL)) biopsy to investigate mitochondrial 
activity using an OROBOROS respirometer. (2) 
An ultrasound (U/S) scan of VL to determine muscle thickness and 
architecture. (2) 
A selection of muscle function assessments. (2) 
Bloods samples to determine myokine and hormone levels. (2)  
A short subjective questionnaire on health perception.  
 
These measures will have been carried out on those participants 
allocated to the RET arm prior to the commencement of the home 
training program. The maximum number of repeats are in parentheses 
above. 
 
In addition to the measures outlined above, rates of muscle protein 
synthesis (MPS) will also be assessed in all participants at baseline and 
throughout the RET for those allocated to that intervention. To facilitate 
this, all participants will be asked to consume a “heavy water” (D2O) 
tracer 24-hours prior to their baseline study visit. For those in the RET 
groups, they will also be asked to consume smaller doses of this tracer 
each week during their RET programme. A saliva sample will be 
collected before and 2-hours after each tracer ingestion. 
 
Participants selected to undergo the RET programme will undergo a 
maximum of 3 sessions per week for up to 4 weeks (minimum 9 
sessions). Following an original teaching session, these RET sessions 
are performed in participants own home, with weekly contact made by a 
member of the research team to maximise participant engagement and 
ensure correct technique. 
 
All baseline measurements will take place at the University of 
Nottingham, Royal Derby Hospital in the week following recruitment at a 
time mutually convenient to the patient and the research team. 
Duration of study Study estimated to last a total of 3-years 
Individual participants will be required to be involved within the study 
from the date they consent to be involved in the study until completion of 
the study. In accordance with national guidelines the preoperative stage 
should be no longer than 31 days from MDT decision to treat. A postal 
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questionnaire will be sent to the participant at 28 days post-surgery. This 
leads us to believe that a single participant would be unlikely to be 
involved with the study for more than 8 weeks for those not requiring 
neoadjuvant chemotherapy and 24 weeks for those who do. 
Randomisation and 
blinding 
Randomisation will occur only for the colorectal and prostate cancer 
patients to determine if they will complete RET. Blinding to an exercise 
intervention is not possible.   
Outcome measures Primary: 
Changes related to cancer and neoadjuvant chemotherapy on; 
Muscle mitochondria function and quantity 
Muscle structure and function 
Body composition 
The relationship between muscle mitochondria function and quantity and 
the other parameters outlined above. 
 
Changes in the above parameters following completion of a 4-week 
home RET regime. 
 
Secondary: 
Changes in myokine and hormone responses (IL-6, TNFα, and TGFβ) to 
cancer. 
Subjective questionnaire data.  
Acceptability of the RET protocol in the pre-operative period. 
 
Safety: 
Adverse event monitoring during RET. 
Statistical methods Data will be analysed using Graphpad Prism by the research team, led 
by the study statistician. After testing for normality, data will be assessed 
using appropriate post-hoc tests to determine differences between the 
cancer groups (one-way ANOVA) and group x time interactions in the 
prostate and colorectal cancer groups. Correlative analysis will be used 
to explore relationships between mitochondrial parameters and other 
physiological data sets.  
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ABBREVIATIONS  
 
Add to / amend accordingly (please ensure ALL abbreviations used in the protocol are listed 
here) 
 
AE Adverse Event 
  
CI Chief Investigator overall 
  
CRF Case Report Form 
  
DMC Data Monitoring Committee 
  
GCP Good Clinical Practice 
  
HIIT High intensity interval training 
 
ICF Informed Consent Form 
 
IPAQ  International Physical Activity Questionnaire 
 
NHS National Health Service 
  
PI Principal Investigator at a local centre 
 
PIS Participant Information Sheet 
 
RDH Royal Derby Hospital 
  
REC Research Ethics Committee 
 
RET Resistance Exercise Training 
 
R&D Research and Development department 
  
SAE Serious Adverse Event 
 
USS Ultrasound scan 
 
UoN University of Nottingham 
 
VL m. Vastus Lateralis 
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TRIAL / STUDY BACKGROUND INFORMATION AND RATIONALE 
Each year, there are around 363,000 new cancer cases in the UK, with almost half of the 
patients going on to have resectional surgery (Cancer Research, 2020). Improving survival 
and quality of life are inherent goals for successful treatment of cancer patients and, as 
such, research is focussing on optimising patient’s health prior to, and during, their cancer 
treatment.  
 
Skeletal muscle represents one of the major compartments of the human body, with its 
function necessary for a variety of biological processes including movement and respiration 
(Porporato, 2016). A tight balance exists between muscle protein synthesis (MPS) and 
breakdown that maintains muscle homeostasis and any disruption in this results in skeletal 
muscle depletion. Although there is a largely unavoidable age-related decline in muscle 
mass and function, known as sarcopenia, patients with conditions such as cancer appear to 
suffer more rapid and extensive loss. This is often referred to as cachexia, a multifactorial 
syndrome characterised by progressive loss in body weight, adipose depletion and 
metabolic abnormalities (Penna et al., 2019). Cachexia is thought to affect 50-80% of 
patients with cancer and directly accounts for 20% of cancer deaths. It is also a known factor 
affecting patient physical performance, causing functional impairment and increasing short 
term postoperative morbidity (Eriksson et al., 2017).  
 
Mitochondria are essential organelles necessary for normal cellular activity and play a crucial 
role in metabolic homeostasis, including the metabolic processes required for the 
maintenance of muscle mass (Pustylnikov et al., 2018). In addition, skeletal muscle is highly 
reliant on mitochondria to meet the energy requirements for contraction, therefore any 
alteration in mitochondrial homeostasis directly impacts muscle function (Antunes et al., 
2014). In animal studies, the presence of cancer has been shown to reduce mitochondrial 
content in skeletal muscle and, as a result led to muscle atrophy. The impact cancer has on 
mitochondrial function, quantity, and its relationship with overall skeletal muscle mass in 
humans remains poorly investigated. 
 
With the established link between cancer cachexia and post-operative morbidity and 
mortality, improving perioperative cardiorespiratory fitness and body composition is of 
increasing clinical importance. In recent years, the term ‘prehabilitation’ has been adopted to 
define a group of interventions, either performed under supervision or at home, that are 
integrated into the clinical pathway prior to surgery. To date these consist mainly of 
combined endurance and resistance exercise. Endurance exercise training is most effective 
for improving cardiorespiratory fitness while resistance training (RET) increases muscle 
mass and function, whilst also promoting improved metabolic function (Piraux et al., 2018). 
These interventions are aimed at both reducing imminent patient risk and promoting lasting 
beneficial effects on perioperative recovery and outcome (Weston et al., 2016).  
 
Since mitochondrial turnover and function are both altered in sarcopenic and cachectic 
muscles, it is hypothesised that pre-operative exercise in cancer patients could act as a 
good counter measure to improve mitochondrial quantity and quality and resultant muscle 
function (Romanello & Sandri, 2016). A number of studies, including those from our own 
research group, have demonstrated an improvement in preoperative cardiorespiratory 
fitness following supervised or home based short term exercise prehabilitation (Boereboom 
et al., 2016; Licker et al., 2017; Weston et al., 2016), however few examine the direct effect 
prehabilitation has on mitochondrial function of cancer patient.  
 
The rationale behind this study is to gain a greater level of understanding of the impact 
cancer and its treatments have on overall muscle function, both at a cellular and whole-body 
level. The study will also assess if any positive changes seen with a regime of home 
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exercise prehabilitation are acceptable and feasible to both the patient and clinician within 
the time restraints of the clinical environment.  
 
TRIAL / STUDY OBJECTIVES AND PURPOSE 
PURPOSE 
To investigate the impact cancer and the various treatment options have on mitochondrial 
quantity and quality, in addition to muscle mass, function and body composition, and 
whether this can be modified through exercise prehabilitation.  
 
PRIMARY OBJECTIVE 
To assess the impact cancer and chemotherapy have on mitochondrial activity. 
 
To assess the impact cancer and chemotherapy have on body composition and muscle 
mass and function. 
 
To investigate if a preoperative exercise program can improve mitochondrial activity, body 




To investigate myokine and hormone levels in the different types of cancer and the impact 
neoadjuvant chemotherapy have on these. 
 
To establish whether there are different responses to exercise training between different 
cancer types.  
 
DETAILS OF PRODUCT(S) 
Description  
No product will be as intervention. The only product to be given is D2O (95% deuterium 
oxide), commonly referred to as “heavy water”. This product will be given to participants 
undergoing muscle biopsies to enable us to quantify rates of muscle protein synthesis 
(MPS). The product is purchased from Sigma-Aldrich, Poole, UK. It is premixed and stored 
in locked medical storage cupboard within the University of Nottingham Clinical Physiology 
Unit. D2O is water containing one “heavy” deuterium atom in the place of a hydrogen atom. 
This method has been used successfully in several previous studies in our laboratory 
including those in pre-operative cancer patients, to quantify protein turnover without the need 
for radioactive labelling or invasive monitoring of participants. D2O is incorporated as a tracer 
into amino acids such as alanine. The fractional synthetic rate of D2O bound to, for example, 
alanine in the muscle vs. the total alanine body pool can then be measured to give rates of 
muscle protein synthesis. It can be assumed that pre-study D2O levels are zero, this will be 
confirmed using plasma protein from the blood sample on the screening visit. Participants 
will then be ‘primed’ with 3mls/kg of D2O 24 hours prior to their baseline study visit.  
 
Manufacture 
Sigma-Aldrich, Poole, UK 
 
Storage, dispensing and return 
It is premixed and stored in locked medical storage cupboard within the University of 
Nottingham Clinical Physiology Unit (Royal Derby Hospital). Each participant will be provided 
with the priming dose of D2O at the time of the screening visit and instructed to ingest the 
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D2O tracer 24 hours before their baseline study visit. If there is any reason the participant is 
illegible to participate in the study following the screening visit, one of the research team will 
contact them and instruct them to dispose of the D2O. 
 
Known Side Effects 
D2O is very well tolerated, and most people have no side effects at all. Self-limiting dizziness 
is the commonest side effect which resolves spontaneously; however, we have previously 
minimised the incidence of this by splitting the initial priming dose into two smaller doses 
which are taken at spaced intervals. This method will be applied in this study. The side effect 
profile is thought to be dose dependent (total body pool enrichment) and we will aim for an 
enrichment level of 0.4% which is well within safe limits as shown previously.  
 
TRIAL / STUDY DESIGN 
TRIAL / STUDY CONFIGURATION 
Single centre pilot study.  
 
Primary endpoints 
Variations related to cancer and neoadjuvant chemotherapy on; 
Muscle mitochondria function and quantity 
Muscle structure and metabolism 
Body composition 
Cardiorespiratory fitness and muscle function  
 
The relationship between muscle mitochondria function and quantity and the other 
parameters outlined above. 
 
Variations in muscle mitochondria function and quantity and the other parameters outlined 
above following completion of a 4-week exercise training regime. 
 
Secondary endpoints 
Changes in myokine (IL-6, TNFα, and TGFβ) and hormone responses preoperatively. 
 
Subjective questionnaire data related to overall health status. 
 




Screening results: physical examination by a qualified doctor, vital signs (pulse rate, BP, O2 
saturations), 12-lead ECG and blood results (FBC, U&E’s, LFT, coagulation screen and lipid 
profile).  
 
Whole study - AEs spontaneously reported during the study, discontinuations due to AEs. 
 
Please see exclusion criteria below for medical conditions inhibiting initial or continued 
inclusion in the study:  
Abnormal results of screening blood tests as detailed below, 
Abnormal screening ECG as detailed below, 
Abnormal clinical measurements e.g., blood pressure, 
Side effects of D2O ingestion.  
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Stopping rules and discontinuation 
Any participant may withdraw from the study at any point, without giving reason.  
Screening tests that indicate renal failure, liver failure, significant anaemia or abnormal 
coagulation would inhibit inclusion. 
An abnormal screening ECG showing any abnormal arrhythmia, 2nd or 3rd degree heart block 
would inhibit inclusion. 
A screening blood pressure of greater than 160/100mmHg would inhibit inclusion. 
 
Exercise training monitoring will comply with the divisional policy on research participation 
set by Dr John Williams, Consultant Anaesthetist. For those participating in the home RET 
training regime, information regarding any adverse reactions to exercise will be explained. 
These include: 
- Chest pain or tightness,  
- Faintness,  
- Sudden pallor,  
- Loss of co-ordination, confusion, dizziness,  
- Signs of respiratory failure 
- Palpitations  
If any such adverse reactions are experienced, the participant would be advised to stop the 
exercise immediately and seek medical advice. 
 
RANDOMIZATION AND BLINDING 
For participants within the study with a diagnosis of breast, oesophageal or colorectal 
(requiring neoadjuvant chemotherapy) cancer, there will be no randomisation taking place as 
the effect of routine treatment will be assessed. 
 
For participants with a diagnosis of prostate or colorectal (not requiring neoadjuvant 
chemotherapy) they will be randomly allocated to either the home resistance exercise 
training (RET) 4-week program or to a control (routine treatment) study arm. This will be 
done using Sealed Envelope, Sealed Envelope Ltd London. This software will randomly 
allocated participants to either group.  A member of the research team who is not involved in 
the data collection or recruitment of participants will generate the randomisation codes and 
keep these securely. Block randomisation using random permuted block sizes of two and 
four will be used. Participants will be stratified according to age and sex to ensure a higher 
likelihood of equal baseline characteristics. Allocation concealment will be ensured by using 
opaque, sealed envelopes with participant group allocation performed on the first visit. Due 
to the nature of the intervention, patients will not be blinded to the intervention or control 
group. However, data collectors will be blinded to the participant’s group assignment. 
 
Independent reviewers of muscle USS will be blinded to both group and pre / post results. 
 
TRIAL/STUDY MANAGEMENT 
Data will be inputted to a secure database with encryption. Consent forms and hard copies 
of data will be kept securely under lock and key in a locked office with access only to named 
researchers on this project. 
 
Mr Jacob Hatt and Mr Thomas Smart (Clinical Research Fellows/ PhD students) will be 
responsible for recruitment and overall conduct of the study including screening, 
physiological and exercise training, data collection in both the University and clinical 
environments and the taking of muscle biopsies. 
 
The Chief Investigator has overall responsibility for the study and shall oversee all study 
management. 
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The data custodian will be the Chief Investigator. 
 
DURATION OF THE TRIAL / STUDY AND PARTICIPANT INVOLVEMENT 
Study Duration: Enrolment will begin as soon as ethical approval has been granted and will 
run until enough participants have been recruited. We anticipate that this project may take 
up to three years to complete in total (Oct 2020 - Mar 2023). 
 
Participant Duration: Individual participants will be required to be involved within the study 
from the date they consent to be involved in the study until completion of the study. In 
accordance with national guidelines the preoperative stage should be no longer than 31 
days from MDT decision to treat. A postal questionnaire will be sent to the participant at 28 
days post-surgery. This leads us to believe that a single participant would be unlikely to be 
involved with the study for more than 8 weeks for those who do not require neoadjuvant 
chemotherapy and 24 weeks for those that do. 
 
End of the Trial:  
The end of the study will be the return of the 28-day questionnaire from the final participant, 
or 6 weeks after this was sent in the case of no questionnaire return. 
 
SELECTION AND WITHDRAWAL OF PARTICIPANTS 
Recruitment 
Potential participants, where there is sufficient evidence confirming suspected cancer 
(breast, oesophageal, prostate, and colorectal), who are eligible for curative treatment 
(surgical resection with or without neoadjuvant chemotherapy) will be identified at weekly 
cancer multi-disciplinary team (MDT) meetings. These individuals will have already been 
informed by a member of their clinical team (either doctor or cancer specialist nurses) of the 
suspicion of the cancer diagnosis and the plan for treatment. 
 
A member of the clinical team will inform potential participants of the study, and provide a 
participant information sheet, giving them chance to read about the study. Contact details for 
the research team will be provided along with the PIS, to allow potential participants to 
contact the research team directly to arrange their screening visit. At the screening visit, a 
member of the research team will go through the patient information sheet and answer any 
questions with the potential participant, prior to obtaining written consent. If needed, the 
usual hospital interpreter and translator services will be available to assist with discussion of 
the trial, the participant information sheets, and consent forms, but the consent forms and 
information sheets will not be printed in other languages. 
 
All participants will give written informed consent immediately once they agree to enter the 
study. This will be prior to the randomisation process (specific to prostate and colorectal 
patients only). We will then allow a minimum of 24 hours before contacting them via 
telephone to answer any further questions about the trial and confirm they are still willing to 
participate. For those participants who could undergo a training regime prior to their 
resectional surgery, the intervention period is severely time limited, and we would aim to 
initiate any training as soon as reasonably possible after the consent and screening process 
is completed. 
 
It will be explained that entry into the trial is entirely voluntary and that their treatment and 
care would not be affected by their decision to participate or not. It will also be explained that 
they can withdraw at any time, but the data collected up to that point would not be erased 
and we would seek consent to use the data in the final analyses where appropriate.  
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All participants will have the results of the histological specimens performed as part of their 
NHS treatment reviewed by a member of the research team following their surgery. All 
participants will be followed up even if their disease is revealed to be benign, however 
further recruitment will be carried out to ensure the numbers assessed with the disease is 
correct. The participants will then be offered to continue in the study if they wish to, however 





1. Aged 50 years and over (no upper age limit) 
2. Histologically confirmed malignancy, radiologically or direct visualisation leading to 
high clinical suspicion of cancer with planned surgical resection as treatment option 
(breast, oesophageal, prostate, or colorectal). 
3. Sufficient mobility to be able to complete resistance exercise (prostate and colorectal 
only). 
4. Capacity to give informed and written consent 
5. Ability to travel to the RDH to complete the assessment session 
 
Exclusion criteria 
1. Current participation in a formal exercise regime  
2. Inability to complete exercise training  
3. A BMI <16.5 or >35 kg/m2 
4. Active cardiovascular disease:  
o Uncontrolled hypertension (BP > 160/100) 
o Angina 
o Heart failure (class III/IV) 
o Significant arrhythmia 
o Right to left cardiac shunt 
o Recent cardiac event  
5. Taking beta-adrenergic blocking agents 
6. Cerebrovascular disease:  
o Previous stroke 
o Aneurysm (large vessel or intracranial) 
o Epilepsy 
7. Respiratory disease including: 
o Pulmonary hypertension 
o Significant COPD 
o Uncontrolled asthma 
8. Clotting dysfunction or current use of anticoagulants (e.g., Warfarin/Clopidogrel/ 
Rivaroxaban) 
9. Significant musculoskeletal or neurological disorders 
 
Removal of participants from therapy or assessments/Participant Withdrawal 
Patients will be withdrawn from the study if they lose capacity for consent or if they wish to 
voluntarily withdraw consent.  
 
Patients will be withdrawn from the study if they suffer any adverse effects of exercise 
training. Patients will be withdrawn from the study if they suffer any adverse effects which 
are attributed to the ingestion of deuterium oxide (D2O) (e.g., nausea, vomiting or abdominal 
pain). This is very unlikely given that D2O is usually well tolerated and has been used 
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extensively in our research group without adverse events. Should this occur, we will refer the 
patient to hospital for further tests and treatment.  
 
Patients recruited into the resistance training arm of the study will be withdrawn from the 
study if they fail to complete a minimum of 8 exercise sessions prior to operation date. If the 
participant wishes to remain in the study, they can be included in the follow up aspect of the 
study following surgery. 
 
Participants may be withdrawn from the trial either at their own request or at the discretion of 
the Investigator. The participants will be made aware that this will not affect their future care. 
Participants will be made aware (via the information sheet and consent form) that should 




All participants will be provided with the details of the trial in depth and given a Participant 
Information Sheet, ensuring that the participant has sufficient time to consider participating 
or not. Once the participant is satisfied with the study, written informed consent will then be 
obtained by the investigator. The Informed Consent Form will be signed and dated by the 
participant before they enter the trial. The Investigator will answer any questions that the 
participant has concerning study participation.  
 
Informed consent will be collected from each participant before they undergo any 
interventions related to the study. One copy of this will be kept by the participant, one will be 
kept by the Investigator, and a third will be retained in the patient’s hospital records. 
 
Should there be any subsequent amendment to the final protocol, which might affect a 
participant’s participation in the trial, continuing consent will be obtained using an amended 
Consent Form which will be signed by the participant
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Key for schematic diagram: Bloods (FBC, UE, LFT, lipid profile, TFT, CRP, HBA1c, glucose), RET = resistance exercise training, 
SPPBT = short performance physical battery tests, QoL = Quality of Life
 
Study day - day of surgery;
Before theatre (30 minutes);
- Height/ weight
- Functional tests (SPPBT, hand grip strength, time up and go)
- Completion of questionnaires (QoL (EQ 5D), IPAQ and end of study)
- Muscle ultrasound
- Blood sample
In theatre (30 minutes);
- Muscle biopsy
Day 28 (1 month)
- Postal completion of questionnaires (QoL (EQ 5D), IPAQ and end of 
study)
End of study


















D2O (3ml/kg) taken 24 hours prior to study day (Saliva sample required prior to taking D2O and two hours post ingestion)
Screening assessment and consent
Pre home RET study day (1 hour):
- Functional tests (SPPBT, hand grip 
strength, time up and go)
- Blood sample
- Muscle ultrasound & biopsy
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Participants will be recruited from surgical outpatient clinics following initial introduction to 
the trial by their clinical team. At this point, they will be provided with a participant information 
sheet. Contact details will be provided on the information sheet to enable potential 
participants to arrange a screening visit. The screening visit would entail a detailed 
description of all study elements and addressing any questions prior to gaining written 
consent. Once the patient provides written informed consent, they will undergo a full 
cardiovascular examination by a medically qualified research team member and will have a 
set of screening bloods taken.  
 
Eligible participants for the home resistance exercise training (RET) program (colorectal and 
prostate cancer patients with no planned neoadjuvant chemotherapy) will be randomly 
allocated to either the training arm of the study or to routine care at this point. 
 
Pre-Exercise study day – For participants within the Home-RET study arm 
Participants randomly allocated to the home-RET study group will attend the University of 
Nottingham Graduate Entry Medical School at the Royal Derby hospital for an assessment 
visit prior to the commencement of their training protocol. Participants will be asked to arrive 
starved from 03:00 of the day. On arrival they will undergo a limited number of physical 
function assessments (including time up and go, hand grip strength, and the short 
performance physical battery test). Following this an ultrasound scan of the thigh to assess 
muscle architecture will be performed.  
A muscle biopsy will be taken from the mid belly of m. vastus lateralis using a conchotome 
biopsy technique. Biopsies will be taken by medically qualified doctors trained and 
experienced in this procedure. The procedure will be performed under aseptic conditions. 
After local anaesthetic, a 5-10mm incision will be made in the skin and underlying fascia and 
a sample of muscle will be taken (approximately 100mg). Direct pressure will be applied to 
achieve haemostasis. A single non-absorbable suture will be placed to allow skin apposition 
and healing. A sterile dressing and compression bandage will be applied to remain in place 
for the duration of the day. The suture will be removed around 5-7 days after the biopsy was 
taken. The biopsy sample will be assessed using an Oroboros respirometer for the primary 
endpoint of mitochondrial activity, analysed by western blotting and PCR to determine cell 
signalling and gene expression. 
Participants will then be provided with a complimentary breakfast, while the training regimen 
is demonstrated to them with time allowed for questions regarding the training regimen. This 
will conclude this study day. 
 
Training program:  
All exercise training will take place in the participants own home. With a documentation pack 
provided to participants to guide exercise and for participants to log their workouts. 
Participants will be asked to perform 3 workouts per week over the 4-week period (12 
workouts in total) with each workout estimated to take 30 minutes maximum. 
Participants will be provided with a set of TheraBand resistance bands to provide resistance 
to their workout. 
As well as the education session provided at the pre-exercise study day, participants will be 
contacted weekly via telephone or video call to encourage participation, to answer any 
difficulties participants maybe experiencing and to ensure no adverse symptoms are being 
experienced. A video will be recorded of a member of the research team performing the 
exercise regimen to enable participants to watch from home. 
  
Each session will include: 
- 2 min warm-up jogging on the spot 
- 2 sets of 12-15 repetitions of: 
• Squats 
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• Hip flexion 
• Hip extension 
• Hip abduction 
• Seated row 
• Bench press 
• Lateral raises 
- 2 min jogging on the spot cooldown.  
 
Each exercise will be separated by 1-minute rest, with participants encouraged to work out 
to mild fatigue on their final repetition in each set. If able to perform more than the allocated 
maximum of 15 repetitions prior to fatigue, then participants will be informed to increase the 
resistance by using a tougher TheraBand. 
  
 
Our research group has conducted many similar exercise regimes of this intensity to 
subjects in the anticipated age-range without incident. Participants will be advised to 
terminate exercise training immediately if experiencing:  
- Chest pain or tightness 
- Faintness 
- Sudden pallor 




- Sudden breathlessness 
 
Should any participant experience these effects during any session, they will be advised to 
seek urgent medical attention and will be withdrawn from the exercise arm of the study for 
safety purposes. 
 
Day of surgery study day – All study participants undertake 
24 hours prior to the study day, participants will be asked to consume a stable isotope tracer 
drink (D2O) at a 3 ml/kg priming dose at home. Participants will be asked to provide saliva 
samples immediately prior to D2O consumption and a further sample 2-hours post 
consumption. Participants will be provided with written instructions, the tracer drinks and 
collection receptacles at their screening visit or via postal delivery for them to collect these 
samples at home. 
 
All participants will attend for their study day fasted from 03:00 of the day, in line with their 
starving instructions for their planned surgical procedure. Participants will first have an 
ultrasound scan of the thigh to assess muscle architecture. Following this, participants will 
be asked to complete a quality-of-life questionnaire (EQ-5D) and a self-administered short-
form international physical activity questionnaire (IPAQ). Venepuncture will be performed to 
gather samples for analysis of myokine expression, and the sputum samples collected at 
home received from the participants. Participants will then perform physical function 
assessments to determine muscle function, including the timed-up-and-go test, and the short 
performance physical battery test.  
 
Once the participant has been anesthetized for their planned surgical procedure, a member 
of the research team will then perform a single muscle biopsy. The muscle biopsy will be 
taken from the mid belly of m. vastus lateralis using the conchotome biopsy technique as 
previously described. 
 
Day 21-28 post-surgery 
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Participants will be contacted by postal survey, and asked to complete a further EQ-5D and 
IPAQ questionnaire, along with a study feedback questionnaire to ascertain participants 
views on the study 
 
As detailed above, in addition to their normal treatments, patients will potentially undergo the 
following invasive or potentially harmful tests according to their limb of study (risks outlined 
in Risk section): two blood tests and a maximum of 2 muscle biopsies. 
 
Compliance 
Compliance with the protocol will be monitored by the member of the research team present 
at every session.  
 
Acceptable compliance for the exercise arm of the study will be defined as completion of a 
minimum of 8 sessions as logged by the participants. Lower than this would be expected to 
result in minimal adaptation and therefore the participant would be excluded from analysis of 
the data but would be welcomed to complete the study. 
 
Criteria for terminating trial 
The study will only be terminated should there be a complete lack of recruitment to the 
study/willing participants. Terminating the whole study may be because of a formal or 
informal interim analysis (data to be analysed after 6 participants) or based on new 
overwhelming evidence of efficacy/inefficacy, major safety concerns, new information, or 
issues with trial conduct (e.g., poor recruitment, loss of resources).  
 
In the event of trial termination, any research data already collected would be kept as 
outlined in the archiving section below, the participants are consented for data storage at the 
beginning of the trial.  
 
RADIATION EXPOSURE 
There is no anticipated additional radiation exposure with participants involvement in the 
study 
 
TRANSPORT AND STORAGE OF THE TISSUES 
Each participant will be assigned a trial identity code number with the prefix ‘IC-Mi’ for use 
on CRF’s (Case report forms), other trial documents, the electronic database, and the 
subject identification log in the trial master file. The documents and database will also use 
the study acronym, initials, and sequential study number e.g.: IC-MiAB_01. Back up of 
electronic files will exist in a password protected program on a password protected computer 
within the chief investigator’s office. 
  
Any blood samples sent to NHS pathology laboratory will be labelled in accordance with 
local procedure. 
  
Only the Clinical Research Fellows (Jacob Hatt and Thomas Smart) and Chief Investigator 
(Jon Lund) will have access to personal information about the participant, this will be 
securely stored in encrypted files away from any samples or other study data. 
  
Human tissue and storage location will be recorded in an anonymised tissue sample log 
stored securely on the local network on a document that is registered with the local HTMG in 
accordance with the human tissue act for compliance and audit purposes. 
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Muscle biopsies: half of the sample (estimated 50mg) will be instantly frozen in liquid 
nitrogen, labelled and stored in a -80-degree freezer. The other half will be placed 
immediately in biopsy preservation solution (BIOPS) prior to being analysed immediately 
within the laboratory. All laboratory analysis will be performed by a suitably trained member 
of the research group within the Clinical Physiology department. 
 
Blood samples will be centrifuged to separate plasma and buffy coat from the samples which 
will be labelled and stored in a -80-degree freezer. 
  
Samples stored for future research will be stored at the research tissue bank at the MRC- 
Versus Arthritis Centre for Musculoskeletal Ageing Research housed within the University of 
Nottingham, Division of Medical Sciences and Graduate Entry Medicine, only if participants 
are agreeable and sign the optional clause on the consent form. 
  
Where participants do not agree to the future use of their samples, they will be destroyed in 
accordance with the Human Tissue Act, 2004. 
 




Blood samples will be sent to chemical pathology within Royal Derby Hospital to be analysed 
for routine health measures (FBC, UE, LFT, Coagulation screen, TFT) and other markers of 
improved health (lipid profile).  
 
Labelling of body water with D2O will be assessed by extraction of the water from the saliva 
samples and analysed using direct liquid injection TC/EA-IRMS. Muscle samples will be 
derivatised to separate out; myofibrillar, sarcoplasmic, lipid, satellite cell and DNA fractions 
according to established procedures in our lab. These fractions will then be analysed via 
GC-pyrolysis-IRMS and GC-MS for deuterium labelling; this combined with the body water 
labelling will allow the calculation of rates of synthesis for each fraction using the standard 
precursor-product model: 
 
Fractional Synthesis Rate (% ⁄ day) = [(APEAla)] ⁄ [(APEP) × t ] × 100 
 
Where APEAla = deuterium enrichment of protein-bound alanine, APEP = mean precursor 
enrichment over the time period, and t is the time between samples. 
 
For additional insight into the mechanisms regulating control of muscle mass and muscle 
protein metabolism we will measure several target proteins within muscle by western blotting 
and real-time PCR. 
 
The muscle sample stored in BIOPS buffer solution will be analysed using a high-resolution 
respirometer to measure cellular oxygen consumption in a closed chamber system 
(Oroboros O2k- FluoRespirometer, Oroboros Instruments) according to an established 
substrate-uncoupler-inhibitor titration (SUIT) protocol developed to assess mitochondrial 
function within permeabilised muscle fibres. 
 
As well as the above blood tests taken for medical screening a venous blood sample will be 
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Objective measures of mitochondrial oxidative phosphorylation (OXPHOS) capacity will be 
analysed for differences between cancer diagnosis groups, and changes seen throughout 
routine cancer treatment as the primary outcome.  
 
Upon study completion data will be analysed using GraphPad Prism, v5.0, (La Jolla, Calif. 
US) and SPSS version 19 (IBM, US), with interim analysis planned after the completion of 6 
participants in each group to ensure correct sample size selection. Data will be analysed in 
house by members of the research team with statistical oversight provided by the study 
statistician.  
 
Distribution of the data will be tested using the Kolmogorov-Smirnov test, with normally 
distributed data expressed as mean (SD) and non-normally distributed data as median +/- 
interquartile range. 
 
The comparison of mitochondrial OXPHOS activity between cancer types will tested against 
the null hypothesis: There is no difference in the mitochondrial OXPHOS activity between 
cancer types. It is anticipated that it will require analysis via a Kruskal-Wallis test (two-tailed, 
multi-variable, un-paired, non-parametric continuous data). 
 
The comparison of mitochondrial OXPHOS activity between the resistance exercise and 
control groups (RET v Con) prior to surgery, this will be tested against the null hypothesis: 
Mitochondrial OXPHOS activity will not be changed by RET when compared to control. This 
is anticipated to require analysis via ANOVA (two-tailed, non-paired, non-parametric 
continuous data with a single variable) 
 
For all data, SPSS v19 software will be used and the significance level will be set at 0.05.  
Analysis of data will be on University of Nottingham computers and backed up to the 
University’s servers.  
 
Sample size and justification 
As this is a pilot study, no power calculation has been performed. This is due to limited 
published evidence on the changes in muscle mitochondrial activity between cancer-types. 
This is also true for the change in muscle mitochondrial activity throughout cancer treatment. 
 
An interim analysis will be performed after the recruitment of 6 participants in each group to 
ensure that sample size selection is correct. 
Assessment of efficacy 
Primary efficacy endpoint:  
The difference in muscle mitochondrial OXPHOS capacity between four cancer types. 
 
Secondary efficacy endpoints:  
 
Mean differences in baseline clinical measures (Such as BP, resting HR, blood chemistry) 
across cancer types 
Differences in body composition, and muscle function between cancers, and its relationship 
with mitochondrial activity. 
The effect of an exercise ‘prehabilitation’ program (4-weeks of resistance-based exercise) on 
muscle mitochondrial activity and muscle function. 
The effect of cancer types on myokine and hormone expression. 
 
See study regime above for timings.  
 
Assessment of safety 
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Due to the current global pandemic situation, several adjustments have been made in the 
protocol to minimise contact as far as possible. When possible, a 2-metre distance will be 
maintained between researchers and participants, and when this is not possible the 
appropriate level of personal protective equipment will be worn by both parties to minimise 
the risk of transmission. Hand sanitiser will also be available for use regularly during periods 
of contact. 
All blood samples and biopsies will be taken by medically qualified, trained individuals.  
Any complication that may occur will be dealt with in accordance with standard NHS 
practice. 
Procedures for missing, unused, and spurious data: Participants will be removed from the 
study if significant amounts of data are missing e.g., greater than 4 exercise sessions 
missed.  
 
Definition of populations analysed 
Safety set: Participants who attend for at least their day of surgery assessment study day. 
Full Analysis set: All participants, who participated in a pre-exercise assessment study day, 
day of surgery assessments, and post-operative postal survey. For participants enrolled in 
an exercise program to complete at least 8 exercise sessions. 
Per protocol set: All participants in the Full Analysis set who are deemed to have no major 
protocol violations that could interfere with the objectives of the study. 
 
Mr Jacob Hatt or Mr Thomas Smart will screen participants for violations of eligibility criteria 
during the consenting procedure. Deviations from the protocol will be assessed by members 
of the research team, primarily by Mr Jacob Hatt or Mr Thomas Smart as adherence and 
compliance to the protocol is monitored by attendance to the sessions.  
 
ADVERSE EVENTS 
The occurrence of an adverse event because of participation within this study is not 
expected and no adverse event data will be collected  
 
ETHICAL AND REGULATORY ASPECTS 
ETHICS COMMITTEE AND REGULATORY APPROVALS 
The trial will not be initiated before the protocol, informed consent forms and participant and 
GP information sheets have received approval / favourable opinion from the Research Ethics 
Committee (REC), the respective National Health Service (NHS) Research & Development 
(R&D) department, and the Health Research Authority (HRA) if required. Should a protocol 
amendment be made that requires REC approval, the changes in the protocol will not be 
instituted until the amendment and revised informed consent forms and participant 
information sheets (if appropriate) have been reviewed and received approval / favourable 
opinion from the REC and R&D departments. A protocol amendment intended to eliminate 
an apparent immediate hazard to participants may be implemented immediately providing 
that the REC are notified as soon as possible, and an approval is requested. Minor protocol 
amendments only for logistical or administrative changes may be implemented immediately; 
and the REC will be informed. 
 
The trial will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, 1996, the principles of Good Clinical Practice, and the  
UK Department of Health Policy Framework for Health and Social Care, 2017. 
 
INFORMED CONSENT AND PARTICIPANT INFORMATION 
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The process for obtaining participant informed consent will be in accordance with the REC 
guidance, and Good Clinical Practice (GCP) and any other regulatory requirements that 
might be introduced. The investigator or their nominee and the participant shall both sign 
and date the Informed Consent Form before the person can participate in the study. 
 
The participant will receive a copy of the signed and dated forms and the original will be 
retained in the Trial Master File. A second copy will be filed in the participant’s medical notes 
and a signed and dated note made in the notes that informed consent was obtained for the 
trial.  
 
The decision regarding participation in the study is entirely voluntary. The investigator or 
their nominee shall emphasise to them that consent regarding study participation may be 
withdrawn at any time without penalty or affecting the quality or quantity of their future 
medical care, or loss of benefits to which the participant is otherwise entitled. No trial-specific 
interventions will be done before informed consent has been obtained. 
 
The investigator will inform the participant of any relevant information that becomes available 
during the study, and will discuss with them, whether they wish to continue with the study. If 
applicable they will be asked to sign revised consent forms. 
 
If the Informed Consent Form is amended during the study, the investigator shall follow all 
applicable regulatory requirements pertaining to approval of the amended Informed Consent 
Form by the REC and use of the amended form (including for ongoing participants). 
 
RECORDS  
Case Report Forms  
All case report forms will be kept in the chief investigators file. This file will be locked within a 
cupboard in a locked office on site.  
 
Each participant will be assigned a trial identity code number with the prefix ‘IC-Mi’, allocated 
at randomisation if appropriate, for use on CRFs other trial documents and the electronic 
database. Each participant will be assigned a trial identity code number for use on CRF’s 
(Case report forms), other trial documents and the electronic database. The documents and 
database will also use the study acronym, 2 randomly chosen letters and sequential study 
number e.g.: IC-MiCaAB01. Back up electronic file will exist in a password protected 
program on a password protected computer within the chief investigator's office. 
 
CRFs will be treated as confidential documents and held securely in accordance with 
regulations. The investigator will make a separate confidential record of the participant’s 
name, date of birth, local hospital number or NHS number, and Participant Trial Number (the 
Trial Recruitment Log), to permit identification of all participants enrolled in the trial, in 
accordance with regulatory requirements and for follow-up as required. CRFs shall be 
restricted to those personnel approved by the Chief or local Principal Investigator and 
recorded on the ‘Trial Delegation Log.’ 
 
All paper forms shall be filled in using black ballpoint pen. Errors shall be lined out but not 
obliterated by using correction fluid and the correction inserted, initialled, and dated. 
The Chief or local Principal Investigator shall sign a declaration ensuring accuracy of data 
recorded in the CRF. 
 
Sample Labelling  
Each participant will be assigned a trial identity code number for use on the samples, 
consent forms and other study documents and the electronic database. The documents and 
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database will also use the study acronym (IC-Mi, initials (of first and last names separated by 
a hyphen or a middle name initial when available) and study enrolment number. 
 
Samples for NHS pathology analysis will be labelled in accordance with local NHS 
procedures.  
 
Source documents  
Source documents shall be filed at the investigator’s site and may include but are not limited 
to, consent forms, current medical records, laboratory results and records. A CRF may also 
completely serve as its own source data. Only trial staff as listed on the Delegation Log shall 
have access to trial documentation other than the regulatory requirements listed below. 
 
Direct access to source data / documents 
The CRF and all source documents, including progress notes and copies of laboratory and 
medical test results shall made be always available for review by the Chief Investigator, 
Sponsor’s designee, and inspection by relevant regulatory authorities (e.g., DH, Human 
Tissue Authority). 
 
DATA PROTECTION  
Paper records will be filed and placed into locked cupboards within a locked office in the 
department of Clinical Physiology, University of Nottingham, Royal Derby Hospital. 
Electronic data will be placed on password protected databases (secure network) on a 
Nottingham University password protected computer within a locked office in the same 
department. 
 
All trial staff and investigators will endeavour to protect the rights of the trial’s participants to 
privacy and informed consent, and will adhere to the Data Protection Act, 2018. The CRF 
will only collect the minimum required information for the purposes of the trial. CRFs will be 
held securely, in a locked room, or locked cupboard or cabinet. Access to the information will 
be limited to the trial staff and investigators and relevant regulatory authorities (see above). 
Computer held data including the trial database will be held securely and password 
protected. All data will be stored on a secure dedicated web server. Access will be restricted 
by user identifiers and passwords (encrypted using a one-way encryption method). 
 
Information about the trial in the participants medical records / hospital notes will be treated 
confidentially in the same was as all other confidential medical information.  
 
Electronic data will be backed up every 24 hours to both local and remote media in 
encrypted format. 
 
QUALITY ASSURANCE & AUDIT  
INSURANCE AND INDEMNITY 
Insurance and indemnity for trial participants and trial staff is covered within the NHS 
Indemnity Arrangements for clinical negligence claims in the NHS, issued under cover of 
HSG (96)48. There are no special compensation arrangements, but trial participants may 
have recourse through the NHS complaints procedures. 
 
The University of Nottingham as research Sponsor indemnifies its staff, research participants 
and research protocols with both public liability insurance and clinical trials insurance. These 
policies include provision for indemnity in the event of a successful litigious claim for proven 
non-negligent harm.  
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TRIAL CONDUCT 
Trial conduct may be subject to systems audit of the Trial Master File for inclusion of 
essential documents; permissions to conduct the trial; Trial Delegation Log; CVs of trial staff 
and training received; local document control procedures; consent procedures and 
recruitment logs; adherence to procedures defined in the protocol (e.g. inclusion / exclusion 
criteria, correct randomisation, timeliness of visits); adverse event recording and reporting; 
accountability of trial materials and equipment calibration logs. 
 
TRIAL DATA  
Monitoring of trial data shall include confirmation of informed consent; source data 
verification; data storage and data transfer procedures; local quality control checks and 
procedures, back-up and disaster recovery of any local databases and validation of data 
manipulation. The Trial Coordinator/Academic Supervisor, or where required, a nominated 
designee of the Sponsor, shall carry out monitoring of trial data as an ongoing activity.  
 
Entries on CRFs will be verified by inspection against the source data. A sample of CRFs 
(10% or as per the study risk assessment) will be checked on a regular basis for verification 
of all entries made. In addition, the subsequent capture of the data on the trial database will 
be checked. Where corrections are required, these will carry a full audit trail and justification. 
 
Trial data and evidence of monitoring and systems audits will be made available for 
inspection by REC as required. 
 
RECORD RETENTION AND ARCHIVING 
In compliance with the ICH/GCP guidelines, regulations and in accordance with the 
University of Nottingham Research Code of Conduct and Research Ethics, the Chief or local 
Principal Investigator will maintain all records and documents regarding the conduct of the 
study. These will be retained for at least 7 years or for longer if required. If the responsible 
investigator is no longer able to maintain the study records, a second person will be 
nominated to take over this responsibility.  
 
The Trial Master File and trial documents held by the Chief Investigator on behalf of the 
Sponsor shall be finally archived at secure archive facilities at the University of Nottingham.  
This archive shall include all trial databases and associated meta-data encryption codes. 
 
DISCONTINUATION OF THE TRIAL BY THE SPONSOR  
The Sponsor reserves the right to discontinue this trial at any time for failure to meet 
expected enrolment goals, for safety or any other administrative reasons.  The Sponsor shall 
take advice from the Trial Steering Committee and Data Monitoring Committee as 
appropriate in making this decision. 
 
STATEMENT OF CONFIDENTIALITY  
Individual participant medical information obtained because of this study are considered 
confidential and disclosure to third parties is prohibited with the exceptions noted above. 
Participant confidentiality will be further ensured by utilising identification code numbers to 
correspond to treatment data in the computer files. 
 
Such medical information may be given to the participant’s medical team and all appropriate 
medical personnel responsible for the participant’s welfare.  
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If information is disclosed during the study that could pose a risk of harm to the participant or 
others, the researcher will discuss this with the CI and where appropriate report accordingly. 
 
Data generated because of this trial will be available for inspection on request by the 
participating physicians, the University of Nottingham representatives, the REC, local R&D 
Departments, and the regulatory authorities. 
 
PUBLICATION AND DISSEMINATION POLICY 
This study will form part of the research fellow’s thesis. No identifiable information will be 
used at all. The results will be published within a peer reviewed journal and international 
presentations will be made.  
 
USER AND PUBLIC INVOLVEMENT 
A recent study undertaken by our unit assessed the effectiveness of an exercise training 
program in an elderly, healthy volunteer group. Following the study all volunteers completed 
a training feedback form. This was designed to assess the acceptably of the intervention to 
the volunteers and provide a mechanism for making the training more acceptable if 
necessary. The volunteers said that the program was enjoyable, it was not a significant time 
burden, it did not interfere significantly with other aspects of their life, and they would 
recommend it to others. 
 
We will use the same training feedback form to assess the acceptability of the training to the 
cancer patients, as well as the other questionnaires as outlined in the protocol. 
 
STUDY FINANCES 
Funding source  
This study is funded by research funds of Mr Jon Lund.  
 
Participant stipends and payments 
Participants will not be paid to participate in the trial; however, a small inconvenience 
allowance will be made available (£10) to contribute towards travel expenses outside of their 
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SIGNATURE PAGES 
 
Signatories to Protocol: 
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